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Fragile X Syndrome presents with a clinical picture of moderate to severe mental
retardation and behavioral abnormalities including autistic features resulting from the loss
of function of a RNA-binding protein, Fragile X mental retardation protein (FMRP). This
work is devoted to the understanding of functional roles of FMRP in normal neuronal
development and in the pathogenesis of the Fragile X Syndrome. Particularly it focuses
on the study of FMRP RNA binding properties, using both mouse models and
biochemical analyses. The disease is usually caused by a triplet repeat expansion in the
5’UTR of the FMR1 gene leading to loss of transcription of FMR1 mRNA, but one
severely affected patient has an isoleucine to asparagine point mutation in one of the
RNA-binding domains of FMRP, hnRNP K homology (KH-type) domain 2. This I304N
mutation has previously been shown to abrogate RNA binding. We generated and
analyzed mouse models harboring the I304N mutation. The mutant protein retains some
normal activities, as it is competent to bind both protein partners such as FXR1P and
FXR2P and, via its RGG-domain, to G-quartet RNA, confirming it is not a completely
functionless denatured protein. However, I304N protein is defective in RNA binding and
is dissociated from polyribosomes. Moreover, electrophysiologic and behavioral deficits
of the I304N mouse reveals that the mutation confers an FMRP-null-like phenotype on
the mouse. These observations support the suggestion that a key function of FMRP in
mediating normal cognition is sequence-specific RNA binding, and heightens the interest
in identifying FMRP-RNA interactions.
To find mRNAs bound by FMRP in mouse brain, we have used UV crosslinking
and immunoprecipitation (CLIP), a new methodology that has several advantages over
conventional methods for identification of bona fide in vivo RNA ligands for RNA
binding proteins. We obtained a defined set of FMRP RNA targets, including previously
validated microtubule associated protein 1b (Mtap1b). These RNA targets encode
proteins of coherent biological functions related to cytoskeletal organization and synaptic
transmission, suggesting FMRP may regulate cytoskeletal dynamics, dendritic and axonal

functions that all converge at the developing synapse. Therefore, loss of FMRP KH2
domain specific RNA binding and proper regulation of RNA metabolism contributes to
the synaptic dysfunction underlying the pathogenesis of cognitive and behavioral deficits
observed in Fragile X Syndrome.
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CHAPTER I. INTRODUCTION
Neuronal RNA binding proteins
Neurons are highly specialized cells that present an impressive complexity. They
have a relatively small cell body but an extensive network of projections and connections,
which in some instances can extend a huge distance away from the nucleus. Neurons can
form neural circuitry through the relay of information between cells at synapses, in order
to communicate with each other. Their complexity in structure and function requires
mechanisms for spatial control and diversity of gene expression. The role of RNA
binding proteins (RBPs) within the nervous system is critical. RBPs can deliver mRNAs
out to neuronal processes and await proper signals to regulate local protein translation.
They alternatively splice pre-mRNAs to generate a versatile repertoire of functionally
different proteins. They regulate at the level of transcription, RNA editing, splicing,
nuclear export, mRNA turnover, localization, and translational regulation. RBPs are
essential in the mechanisms underlying neurogenesis, neurite growth, synapse formation,
and plasticity in neurons. Subsequently, there is direct association between neurological
diseases and perturbation of RBP activity and RNA misregulation. Here we introduce a
few prototypical examples of RBPs to elucidate their diverse roles in neuronal function
and development.
-Splicing (Nova)
Nova family proteins were initially discovered as target onconeural antigens of
the neurodegenerative disorder paraneoplastic opsoclonus-myoclonus ataxia (POMA),
found in a small fraction of patients with tumors of the breast, lung and fallopian tubes.
Nova family proteins are expressed solely in the central nervous system (CNS), an
immune privileged site, and for this reason they are seen by the immune system as
“foreign” antigens. When they are ectopically expressed in systemic tumors, they elicit an
immune response that may suppress the tumor growth but simultaneously targets the
CNS leading to neuronal death and neurological impairment (Albert et al., 2000; Albert
et al., 1998; Buckanovich et al., 1993; Darnell and Posner, 2003; Musunuru and Darnell,
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2001). As the name suggests, POMA is a syndrome marked by a loss of inhibitory motor
control in the motor neurons leading to rapid irregular eye movement (opsoclonus),
muscle spasm (myoclonus) and failure of coordination (ataxia) (Darnell, 2004, 2006).
Nova family proteins harbor three KH-type (hnRNP K homology) RNA binding domains
(RBD) (Siomi et al., 1993a). Nova proteins, predominantly nuclear, preferentially bind to
YCAY repeats in exons or introns and have been well characterized to influence
alternative splicing of pre-mRNAs coding for a network of synaptic proteins (Dredge and
Darnell, 2003; Jensen et al., 2000a; Jensen et al., 2000b; Ule et al., 2003; Ule et al., 2006;
Ule et al., 2005b). Nova-1 knockout mice show action tremors and difficulty walking,
symptoms similar to those of POMA patients. Apoptotic death of motor neurons is seen
in these mice. They ultimately die at 1-2 weeks of age (Jensen et al., 2000a). Nova-2
knockout mice have a lesser degree of ataxia and die at approximately 2-3 weeks; slow
inhibitory post-synaptic current (sIPSC) mediated by metabotropic GABA(B) receptors is
abolished in Nova-2 null mice (Huang et al., 2005).
-mRNA stability (Hu)
Another family of RBPs, also onconeural antigens, is the Hu proteins, which are
involved in the development of paraneoplastic encephalomyelitis and sensory neuropathy
(PEM/SN), most commonly associated with small cell lung cancer (SCLC) (Darnell,
2004, 2006). Among the Hu family, HuB, C, and D are neuron specific while HuA (HuR)
is ubiquitously expressed (Brennan et al., 2000; Deschenes-Furry et al., 2006; Keene,
1999; Okano and Darnell, 1997). Hu family proteins harbor three RNA recognition
motifs (RRMs). The best understood function of Hu proteins is a cytoplasmic role in
binding specifically to AU-rich elements (ARE) found in the 3’UTR thereby stabilizing a
few developmentally regulated transcripts, e.g. c-fos, c-myc, N-myc, p21waf1, neuroserpin
and MARCKS (Brennan et al., 2000; Deschenes-Furry et al., 2006; Keene, 1999).
Additional functions of Hu have also been shown. For instance, HuD contains a nuclear
export signal and interacts with mRNA export receptor TAP/NXF1 to regulate nuclear
export. Furthermore, studies show that when shuttling of HuD is blocked, neurite
elongation is severely impeded, suggesting that HuD plays an important role in
trafficking and localizing its transcripts, e.g. Tau mRNA is targeted to axons and GAP-43
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to growth cones (Deschenes-Furry et al., 2006). Finally Hu bound mRNAs are also
targeted to ribosomes and polyribosomes, e.g. HuB and neurofilament-M mRNA.
Therefore, Hu could also be involved, directly or indirectly through interacting with other
RBPs, in translational control (Deschenes-Furry et al., 2006). HuD knockout mice,
despite the presence of other family members, still display motor/sensory defects such as
abnormal clasping reflexes of the hind limbs and poor rotarod performance (Akamatsu et
al., 2005). In HuD deficient primary neurospheres, the number of slowly dividing stem
cells in the adult subventricular zone is increased while the number of differentiating
quiescent cells is decreased (Akamatsu et al., 2005), suggesting HuD is required at
multiple points during neuronal development.
-mRNA localization (ZBP1)
Zip code binding protein 1 (ZBP1) has been discovered as an RBP to the
conserved 54-nucleotide element, the zipcode, in the 3’UTR of β-actin mRNA (Ross et
al., 1997). ZBP1 harbors two RRM domains in its N-terminal portion and four KH
domains in its C-terminal portion, placing it in the highly conserved VICKZ (Vg1
RBP/Vera, IMP-1, 2, 3 (insulin-like growth factor II mRNA binding protein), CRD-BP
(c-myc coding region determinant-binding protein), KOC (KH-domain-containing
protein overexpressed in cancer), ZBP-1) family of RBPs (Yisraeli, 2005). Diverse roles
in RNA metabolism are seen among these closely related proteins. The main function of
ZBP1 has been shown to localize β-actin mRNA to filopodia where local synthesis of βactin and polymerization occurs in developing neurons (Bassell et al., 1998; Zhang et al.,
2001a). In cultured hippocampal neurons, knocking down ZBP1 reduces dendritic β-actin
mRNA levels and leads to the loss of dendritic filopodia and synapse formation (Eom et
al., 2003). Conversely, overexpression of an (EGFP)-beta-actin construct, which contains
the zipcode, recruits endogenous ZBP1 to dendrites and increases the density of dendritic
filopodia and filopodial synapses (Eom et al., 2003). Therefore, ZBP1 appears to mediate
mRNA localization, which in turn regulates dendritic morphology and synaptic growth.
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-Translational control (FMRP)
Our work focuses on the study of fragile X mental retardation protein (FMRP).
Functional absence of this RBP is associated with the most common form of inherited
mental retardation, the Fragile X Syndrome (FRAXA). The incidence is about 1 in 4000
males and 1 in 8000 females. Affected patients have moderate to severe mental
retardation, macroorchidism, autistic features, attention deficit hyperactive disorders,
seizures, and connective tissue dysplasia leading to a characteristic appearance of a long
narrow face and large ears (Jin and Warren, 2000, 2003; O'Donnell and Warren, 2002).
In most cases the disease is caused by the expansion of a CGG repeat in the 5’ UTR
region and methylation of CpG islands that lead to subsequent loss of FMRP expression
(Jin and Warren, 2000, 2003; O'Donnell and Warren, 2002). As a result of CGG-repeat
expansion, typical fragile X patients display a folate-sensitive breakage site at
chromosome Xq27.3 upon cytogenetic analysis—hence the name “fragile X.”
-Fmr1 gene
FRAXA is one of the pioneer examples of one gene being responsible for one
disease; however, cloning the Fmr1 gene has not been easy. A great deal of genetic and
physical mapping has been done to mark the fragile site. A yeast artificial chromosome
(YAC) containing markers known to flank the fragile site has been identified, and it
contains a CpG island that is aberrantly methylated in fragile X patients (Heitz et al.,
1991). Finally, the laboratories of Nelson, Oostra and Warren have used this same YAC
to probe a human brain cDNA library and clone the Fmr1 gene responsible for the
disease (Verkerk et al., 1991), and the absence of Fmr1 expression has been verified in
majority of fragile X patients (Pieretti et al., 1991). Fmr1 spans 38 kilobases (kb) and
encodes a 4.4kb transcript consisting of 17 exons, which are subject to alternative
splicing (Ashley et al., 1993a; Eichler et al., 1993). Fmr1 has two autosomal paralogs,
FXR1 and FXR2, which make up the Fragile X-related (FXR) family members (Siomi et
al., 1995; Zhang et al., 1995). Gene structure is highly conserved amongst the three
family members, indicating that they are derived from a common ancestral gene
(Kirkpatrick et al., 2001). In Drosophila, there is only a single ortholog, dfxr (Wan et al.,
2000).
4

-FMRP RNA and protein interactions
FMRP is almost ubiquitously expressed with the highest expression observed in
brain and testes; however, in the nervous system, its expression is restricted to neurons.
FMRP is characterized by multiple RNA binding motifs, two tandem KH (hnRNK
homology)-type RNA binding domains (Siomi et al., 1994; Siomi et al., 1993b), a spacer
region, and an arginine and glycine-rich RNA binding domain (RGG box) (Siomi et al.,
1993b). The N-terminus may also have RNA binding ability as assessed by a
ribohomopolymer assay (Adinolfi et al., 1999). However, the identification of FMRP
RNA targets has not been a trivial task. Many laboratories have attempted this with
various approaches (Brown et al., 2001; Chen et al., 2003; Darnell et al., 2005a; Darnell
et al., 2001; Dolzhanskaya et al., 2003; Miyashiro et al., 2003; Muddashetty et al., 2007;
Sung et al., 2003; Todd et al., 2003; Xu et al., 2004; Zalfa et al., 2003; Zhang et al.,
2001b) (see Chapter IV Introduction for details), and a long list of RNA candidates has
been generated. However, due to some intrinsic uncertainties underlying each technique,
these targets have limited overlap, making it difficult to distinguish true FMRP targets
from falsely-identified ones. Therefore, identifying a set of reliable FMRP RNA targets is
still highly necessary. So far the most believed and functionally-validated target,
combining both biochemical analysis and Drosophila genetics, is Mtap1b mRNA (Brown
et al., 2001; Zhang et al., 2001b).
Aside from binding to RNA, FMRP has been reported to be in complex with
many other proteins. Its N-terminal domain has been characterized by NMR structures
and deletion studies as a platform for protein-protein interactions (Adinolfi et al., 2003;
Mazroui et al., 2003; Ramos et al., 2006). FMRP interacts with FXR1P and FXR2P in
mouse brain (Ceman et al., 1999; Tamanini et al., 1999; Zhang et al., 1995). Yeast 2
hybrid assays have also identified NUFIP1 (Bardoni et al., 1999), CYFIP1 and CYFIP2
(Schenck et al., 2001), which are shown in Drosophila to interact with Rac GTPase
pathway that controls actin cytoskeleton remodeling (Schenck et al., 2003), and 82-FIP
(Bardoni et al., 2003). Nucleolin, YB1/p50, Purα, mStaufen, and myosin Va have also
been shown to be components of FMRP containing complexes (Ceman et al., 1999;
Ceman et al., 2000; Ohashi et al., 2002), although evidence for their direct interaction
5

with FMRP is not sufficient. In Drosophila, dFXR has been found to interact
biochemically with Argonaute 2 (dAgo2), a key component of the RNA-induced
silencing complex (RISC) (Caudy et al., 2003; Caudy et al., 2002; Ishizuka et al., 2002)
and genetically with dAgo1 (Jin et al., 2004). In mammalian cell cultures, FMRP and
FXR1P have been shown to co-immunoprecipitate with mAgo2 (ortholog of dAgo1) (Jin
et al., 2004; Vasudevan and Steitz, 2007).
-FMRP role in translational control
Despite our knowledge of FMRP multiple functional domains and interacting
partners, the precise physiological functions of FMRP have not been defined. The most
likely function of FMRP, given the sum of the current literature in the field, is in
translational regulation. A strong piece of evidence is that FMRP is on polyribosomes in
cell culture and mouse brain in an RNA-dependent manner (Corbin et al., 1997; Feng et
al., 1997a; Feng et al., 1997b; Khandjian et al., 1996; Khandjian et al., 2004; Stefani et
al., 2004). FMRP has been shown to be a translational inhibitor in rabbit reticulocyte
lysate and in over-expressed cell culture, but these studies used candidate mRNAs which
have little overlap with identified FMRP targets (Laggerbauer et al., 2001b; Li et al.,
2001; Mazroui et al., 2002; Zhang et al., 2001b); both systems are also considerably
different from endogenous cellular environment. The best in vivo evidence comes from
combined biochemical data and Drosophila genetics. Mutations of futsch/Mtap1b or dfxr
alone lead to aberrations in architecture of neuronal synapses, but double mutation
restores synaptic architecture (Zhang et al., 2001b). Together with the findings that
Mtap1b mRNA coprecipitates with FMRP and has increased association with
polyribosomes (Brown et al., 2001), these data have support the model that FMRP
negatively regulates translation of Mtap1b mRNA. In addition, FMRP has been proposed
to regulate local translation. The evidence comes from FMRP trafficking to dendrites and
synapses after stimulation of metabotropic glutamate receptor (mGluR) and is dependent
on microtubules (Antar et al., 2004; Antar et al., 2005; De Diego Otero et al., 2002). A
few FMRP target mRNAs encoding synaptically localized proteins (PSD95, GluR1/2,
and CamKIIa) have been shown to have increased polyribosome association in
synaptoneuorosome preparations in absence of FMRP (Muddashetty et al., 2007),
6

suggesting FMRP as a local translational repressor. Moreover, the relatively new finding
of dFXR association with RISC components implies that FMRP may also repress
translation via microRNAs (miRNAs) (Caudy et al., 2003; Caudy et al., 2002; Ishizuka et
al., 2002; Jin et al., 2004). Recently, one unbiased screen has identified FXR1P in
complex with mAgo2 binding to AREs. Instead of repressing translation, FXR1P and
mAgo2 were shown to up-regulate translation, likely through a different miRNA
mediated mechanism (Vasudevan and Steitz, 2007). Due to the common ancestry of
FMRP and FXR1P, this finding suggests that FMRP may be a translational enhancer, too.

Understanding translational regulation
Translation of mRNA into protein represents the final step in the gene expression
pathway. Control of translation is a mechanism to fine-tune protein expression levels in
both time and space in a wide range of biological situations. Two general modes of
control can be envisioned: 1) global control, in which the translation of most mRNAs in
the cell is regulated, and 2) mRNA specific control, whereby the translation of a defined
group of mRNAs is modulated without affecting general protein synthesis or translational
status as a whole.
Translation of an mRNA to cognate protein proceeds in three sequential steps of
initiation, elongation, and termination and regulation can occur at any of these steps.
During initiation, an eIF2⋅GTP⋅Met-tRNAi ternery complex binds to 40S ribosomal
subunit to form a 43S pre-initation complex. The 43S complex is recruited to the
initiation condon of the mRNA to form a stable 48S complex, which is assisted by a set
of factors from the eIF4 family. These factors subsequently dissociate, the 60S ribosomal
subunit joins the 40S subunit to form the 80S complex, and elongations ensues. During
elongation, eEF1A and eEF1B guide aminoacyl-tRNAs to the A site on the ribosome;
following peptide bond formation, eEF2 mediates the ribosome translocation by one
codon along mRNA. Finally, termination at a stop codon is mediated by a set of release
factors. eEF1 structurally and functionally mimics tRNA to decode stop codons and
promote ribosome-catalyzed peptidyl-tRNA hydrolysis, releasing nascent polypeptide
chain (Sonenberg et al., 2000).
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-Global translational control
Global regulation mainly occurs by the modification of translation initiation
factors. One prototypical example is of cap-binding protein eIF4E availability. Interaction
of eIF4E with scaffold protein eIF4G is required for cap-mediated recruitment of the 43S
ribosomal complex to mRNA. eIF4E-binding proteins (4E-BPs) compete with eIF4G for
the interactions with eIF4E, preventing recruitment of the 43S complex and resulting in
translational inhibition. Following brain-derived neurotrophic factor (BDNF) stimulation,
activation of PI3K/Akt/mTOR signaling pathway has reported in neurons to
phosphorylate 4E-BPs rendering it to dissociate from eIF4E, therefore enable eIF4E and
eIF4G interaction to start translation (Takei et al., 2004; Takei et al., 2001).
-mRNA specific regulation of translation
mRNA specific regulation of translation on the other hand is driven by regulatory
protein complexes that recognize particular elements present on the target mRNA. A
special and very interesting example of mRNA specific regulation is the local regulation
of translation that occurs in polarized cells, such as neurons. The purpose is to generate a
protein gradient or to restrict protein expression to a small defined region, e.g. synapses.
Translational initiation is typically rate limiting and thus often a target for
regulation. Here are a few well-characterized examples of mRNA specific translational
control at various steps of the initiation stage. Cytoplasmic polyadenylation element
binding protein (CPEB) binds to a uridine rich cytoplasmic polyadenylation element
(CPE) located in the 3’UTR of target mRNA, e.g. dendritic CamKIIα (Wu et al., 1998).
In response to NMDAR activation, CPEB is phosphorylated by aurora kinase. After
phosphorylation, CPEB binds CPE in CamKIIa 3’UTR and recruits poly(A) polymerase
to polyadenylate the mRNA. Polyadenylation promotes the dissociation of Maskin from
eIF4E, thus “unmasking” eIF4E, so local translation of CamKIIα is activated (Huang et
al., 2002; Wells et al., 2001; Wu et al., 1998). Iron regulatory proteins (IRP)1 and 2 bind
a stem loop sequence, iron responsive element (IRE), in the 5’UTRs of ferritin heavy and
light-chain mRNAs within 40 nucleotides of the cap structure. IRP1 and 2 sterically
block the 43S ribosomal complex recruitment to ferritin mRNA that is engaged with
eIF4F complex, thereby preventing translation initiation (Gray and Hentze, 1994;
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Muckenthaler et al., 1998). CPEB targets the formation of eIF4F complex, whereas IRPs
allow the cap binding complex eIF4F to bind mRNA, but blocks 48S ribosomal complex
recruitment. Still a later step of translation initiation, formation of the 80S ribosomal
complex is regulated by hnRNP K and hnRNP E1. They bind to a CU-rich repeat
element, also known as differentiation-control element (DICE) that is located in the
3’UTR of 15-lipoxygenase (LOX) mRNA. Sucrose gradient analysis has been used to
show that 48S complex formation occurrs, but 80S momosome formation is inhibited.
hnRNP K and hnRNP E1 prevented joining of the 60S ribosomal subunit by interfering
with translational initation factors. hnRNP K and E1 translational regulation of LOX
mRNA is bypassed in IRES-dependent translation, since IRES does not require any
translational initiation factors (Ostareck et al., 2001; Ostareck et al., 1997; OstareckLederer and Ostareck, 2004).
Translational control can also be achieved through regulation at the elongation
stage mainly for two reasons. First is to maintain translational fidelity, since it is
inversely related to elongation activity (Carr-Schmid et al., 1999). Second, when
translational elongation is inhibited, polyribosomes are still retained, which will allow
translation to resume rapidly when needed. One such protein that regulates elongation is
eEF2, which mediates ribosome translocation from one codon to the next. Two major
signaling mechanisms—Ca2+ (shown in amphibian tectum and rat inferior colliculi) and
cAMP (shown in cardiac myocytes) activate Ca2+/calmodulin dependent kinase III
(CamKIII), which phosphorylates eEF2. Phosphorylated eEF2 becomes inactive and
switches off elongation (McLeod et al., 2001; Scheetz et al., 1997, 2000). Increased
cAMP by activation of protein kinase A (PKA) is usually seen under conditions of
increased energy demand, therefore putting a brake on elongation, which is the most
energy consuming step of translation in order to conserve the energy for more urgent
purposes.
-miRNA mediated translational control
Perhaps the most recent and exciting area of translational control is miRNA
dependent translational repression. They are small RNA molecules of ~22 nucleotides in
length that hybridize by incomplete base pairing, usually to the 3’UTR of target mRNAs.
9

The first miRNAs discovered were lin-4 and let-7, which are crucial for regulating
developmental timing in Caenorhabditis elegans. Because the target mRNA remains
intact after miRNA binding, miRNAs are believe to repress translation rather than
degrading mRNA. The mechanism for repression is largely unknown. The initial
hypothesis has been that miRNAs mediate repression of gene expression after the
initiation step, since translational repression of lin-14 mRNA by lin-4 miRNA does not
alter lin-14 mRNA association with polyribosomes (Engels and Hutvagner, 2006). This,
however, has been challenged when a few laboratories have reported miRNA mediated
repression can skew some mRNAs toward the top of the polyribosome gradient and can
be bypassed in IRES-dependent translation, suggesting miRNA inhibition of translation
can also happen at the initiation step (Humphreys et al., 2005; Pillai et al., 2005). Yet
another development is that Argounate proteins, miRNAs, and their target mRNAs can
accumulate in cytoplasmic foci, known as P-bodies (processing bodies), where
translational repression happens (Jackson and Standart, 2007). It is still unknown how
RBPs may play a role in miRNA dependent translational regulation, but a role in helping
miRNAs bind the correct mRNA is worth exploring.

Modeling human neurological disease in animals
Identification of disease-associated genes has facilitated the understanding of
many diseases, especially in the realm of diagnosis. Animal models provide a link
between the lesion of a gene and the pathologic manifestation of a disease. Mice, for
instance, share important physiological, anatomical, and genomic similarities with
humans. Fine genetic manipulation in animal models enables us to tease out the steps of
disease-causing mechanisms in a physiologically-relevant system. Lastly, animal models
also allow us to test possible treatments in a living organism. Here we provide a few
examples of modeling a few neurological diseases using transgenic, knockout, knock-in,
and conditional knockout mice.
-Modeling Spinal muscular atrophy
Spinal muscular atrophy (SMA) is a recessive genetic disease of spinal motor
neuron degeneration, muscle denervation, and atrophy. More than 95% of patients have
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been identified to carry a partial or complete deletion of the telomeric survival of motor
neuron gene (SMN1). SMN1 has a highly homologous centrimeric copy, SMN2, of
which all SMA patients carry at least one intact copy. As SMA is a recessive disorder, it
is believed that remaining levels of SMN protein can govern the severity of the disease in
patients. A combination of different SMA mouse models has provided valuable insights
to the understanding of the disease. Unlike in human, there is only one mouse SMN
ortholog, and knockout of mouse SMN results in early embryonic lethality (Schrank et
al., 1997). Transgenic mice, which allow ectopic expression of human SMN2, have been
generated, and these mice have been crossed onto the SMN knockout background. These
SMN knockout and human SMN2 transgenic mice have survived and recapitulated the
motor neuron death in the spinal cord and skeletal muscle abnormalities of the human
disease (Hsieh-Li et al., 2000; Monani et al., 2000). Transgenes can insert in the genome
in tandem repeats, resulting in lines of high and low expressers. Utilizing differential
SMN expression of these transgenic mice, it has been shown that high expressers produce
a milder phenotype than low expressers, confirming belief that the level of SMN protein
inversely correlates with the disease severity. Conditional knockout mice of SMN, which
utilize the Cre-LoxP recombination system and allow tissue specific knockdown of the
gene, have further elucidated the mechanism behind muscle denervation. Neuron specific
ablation of SMN resulted in morphological changes in motor neuron and skeletal muscle
denervation, providing evidence that motor neurons are the primary target of SMN
(Frugier et al., 2000). Interestingly, muscle specific SMN knockout mice have a
dystrophic phenotype that causes paralysis, indicating that SMN defect in skeletal muscle
may also have a role in SMA pathogenesis (Cifuentes-Diaz et al., 2001).
-Modeling Rett Syndrome
Rett syndrome (RTT) is a neurodevelopment disorder that predominantly affects
females who show normal development for 6-18 months but then enter a period of
regression in which motor and language skills are lost. Mutations in the gene encoding
methyl-CpG binding protein 2 (MeCP2) cause RTT. MeCP2 is on the X chromosome,
therefore the affected females are mosaic due to X chromosome inactivation (XCI).
Patients with XCI skewed toward mutant allele inactivation have milder symptoms. The
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same mutation in males causes a more severe phenotype, e.g., neonatal encephalopathy or
infantile death. To model the disease, MeCP2 knockout mice have been generated and
show hypoactivity, abnormal breathing, uncoordinated gait, and death at 6-12 weeks of
age (Guy et al., 2001), replicating the severe disease found in infant males. Brain specific
MeCP2 knockout mice show a similar phenotype as the MeCP2 knockout (Chen et al.,
2001), indicating the loss of MeCP2 in the CNS alone is sufficient to cause the disease,
despite MeCP2 expression in many other tissues. Finally, a knock-in strategy has been
used for generation of a hypomorphic truncation mutation of MeCP2 308 recapitulating
many features of classic RTT in male mice, bypassing the complication of XCI of
heterozygote females (Shahbazian et al., 2002). These RTT mouse models,
complementing one another, are valuable systems in which functions of MeCP2 are
examined.

-Fragile X Syndrome animal models
A pathogenetic link between the lesion in the FMR-1 gene and the fragile X
phenotype has been established by the generation of FMR-1 knockout mice. These mice
bear many similarities to human patients. They have significant macroochidism (DutchBelgian Fragile X Consortium, 1994) and abnormally-long, tortuous dendritic spines
(Comery et al., 1997; Nimchinsky et al., 2001). They exhibit defects in behavior and
learning, e.g., hyperactivity, decreased level of anxiety (Dutch-Belgian Fragile X
Consortium, 1994; Peier et al., 2000), and increased sensitivity to audiogenic seizure
(Chen and Toth, 2001; Musumeci et al., 2000). Electrophysiologic studies on these mice
have shown they have enhanced mGluR-dependent long term depression (LTD) in the
hippocampus that persists in the absence of de novo protein synthesis (Huber et al., 2002;
Nosyreva and Huber, 2006), suggesting a synaptic plasticity defect underlying the fragile
X biology. Enhanced mGluR dependent LTD has also been observed at parallel fiber
synapses in cerebellum in Purkinje cell specific Fmr1 knockout mice. Purkinje specific
knockout of FMRP alone is sufficient to cause defect in classical delay eye-blink
conditioning in these mice (Koekkoek et al., 2005), which later has been demonstrated in
human patients. In addition to modeling the various defects of the Fragile X Syndrome,
the knockout mice have already been used widely in comparison to wild type mice in
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various validation assays to elucidate functional roles of FMRP. Furthermore, trials of
clinical treatments targeting mGluR signaling pathway have already been undertaking
using these mice as a model system for the human disease.
In addition to Fmr1 knockout mice, Fmr1 YAC transgenic mice, an overexpresser of human FMR1, have been generated and functionally rescued the knockout
phenotype, shown by behavioral assays and testicular phenotype (Peier et al., 2000).
Additionally, over-expression of FMRP causes an opposite phenotype, implying the level
of FMRP is likely to be tightly regulated in vivo; a moderate overproduction can harbor
its own phenotype.
FMRP has two functional paralogs, FXR1P and FXR2P, which are derived from
the same ancestral gene (Kirkpatrick et al., 2001). A genetic system like Drosophila
where there is only one ortholog, dfxr, can be used to knock out all three family
members. Dfxr mutant flies exhibit phenotype in many ways similar to Fmr1 knockout
mice. They have increased synaptic growth at the neuromuscular junction, arrhythmic
circadian activity, reduced courtship, and impaired coordinated behavior (Dockendorff et
al., 2002; Inoue et al., 2002; Morales et al., 2002; Zhang et al., 2001b). However, no one
has yet rescued the Drosophila phenotype with a mammalian Fmr1 gene. Therefore,
FXR1 and FXR2 knockout mouse models have each been generated. FXR1 knockout
mice have a striated muscle defect and unfortunately die shortly after birth likely due to
cardiac or respiratory failures (Mientjes et al., 2004). FXR2 knockout mice exhibit many
behavioral abnormalities overlapping with Fmr1 knockout mice (Bontekoe et al., 2002;
Spencer et al., 2006). Indeed, Fmr1/FXR2 double knockout mice showed an exaggerated
behavioral phenotype (Spencer et al., 2006), suggesting that FXR family proteins may
function synergistically; one possibility for the relatively mild phenotype in the Fragile X
Syndrome may be due to the functional redundancy of its paralogs.
All these mouse models so far are a loss or gain of the entire FMRP protein.
Because FMRP consists of multiple functional domains, it has been difficult to determine
which domain’s loss of function is critical for the pathogenesis of the disease until a
single fragile X patient was reported to harbor a de novo isoleucine to asparagine
mutation in KH2 RNA binding domain (DeBoulle et al., 1993). He has the clinical
stigmata of severe fragile X syndrome: coarse acromegaloid features, a large forehead, an
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asymmetric long face, large ears, thick lips, mandibular prognathism, focal seizures, and
impressive macroorchidism with both testicles exceeding 100ml volume. This I->N
mutation has previously been shown by our lab and others to abolish RNA binding by
this and similar KH-type RBDs, therefore offering hope of focusing FMRP studies in a
key functional domain. A mouse model of this specific mutation will be highly valuable
to understand how the loss of specific functions of FMRP in normal neuronal biology
contribute to the defects in neuronal function seen in Fragile X Syndrome.
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CHAPTER II. EXPERIMENTAL PROCEDURES
Generation of targeted Fmr1 I304N knock-in mutation
A genomic clone encoding Fmr1 was isolated from a BAC library derived from a 129
mouse (ES-129/SvJ BAC library, clone address 217I21, Incyte Genomics). To generate a
Fmr1 KH2 I304N targeting vector, we first cloned a 7.2 kb BamHI-XhoI 5’ homology
arm spanning from intron 5 to intron 9 into pBSK plasmid. Simultaneously we cloned a
1.9kb XhoI-KpnI fragment including the I304N mutation and 3’homology arm (1.3kb).
On the XhoI-KpnI fragment, PCR mutagenesis generated the I304N mutation in exon 10
(as well as a new HindIII site) as well as a new XbaI site in the middle of intron 10 that
showed divergence in the mouse and human sequences. The loxP-Auto-Cre-NeoR-loxP
(ACNF) cassette was inserted in this novel XbaI site. Finally, the 5’ homology arm and
the XhoI-(I304N)-(ACNF)-KpnI fragment were ligated together into pBSK plasmid. The
plasmid was linearized by NotI and used to electroporate ES cells at the Transgenic
Services Laboratory at The Rockefeller University. Genomic DNA from individual
colonies was digested with BamHI and screened by Southern blot analysis. The Southern
probe overlapping exon 12, which had no corresponding sequences in FXRs (Kirkpatrick
et al., 2001), would distinguish the targeted allele, 2.7kb, from wild type locus, 9.6 kb.
Correctly targeted clones were selected for blastocyst injection and transferred to
pseudopregnant females, from which germline chimeras were obtained.

Generation of Fmr1 I304N BAC transgenic mice
The I304N mutation was inserted into BAC clone encoding Fmr1 by the homologous
recombination protocol of Heintz and colleagues (Yang et al., 1997). In short, a shuttle
vector was cloned comprising 1kb of genomic sequence centered on the I304N mutation,
the recA recombinase gene, tetracycline resistance cassette, and a temperature-sensitive
origin of replication. E coli of DH10B strain harboring Fmr1 BAC, which also contains a
chloramphenicol resistance cassette, were transformed with the shuttle vector and doubly
selected for tetracycline and chloramphenicol first at 30oC and then 43oC for cointegration of Fmr1 BAC and I304N shuttle vector. Co-integrated clones were then
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grown at 43oC in the presence of chloramphenicol to allow the resolution of shuttle
vector from BAC. Resolved clones were screened by PCR for the presence of I304N
mutation. I304N BAC plasmid DNA was then prepared by cesium chloride gradient
ultracentrifugation, digested with NotI, purified, buffer exchanged to high salt injection
buffer, and finally injected into pronuclear oocytes of the inbred FVB/N strain by the
Transgenic Services Laboratory at The Rockefeller University. Germline transmission of
the transgene was seen with two female Fmr1 I304N founders, A and B, which were then
bred to the Fmr1 null background. One wild type transgenic founder was also obtained as
control.

Histopathology and testicular measurement
Three I304N knock-in mice and three wild type littermates were sacrificed and tissues
fixed in 10% formalin overnight and embedded in paraffin blocks. Tissue sections were
deparaffinized, rehydrated, stained with hematoxylin & eosin, and visualized with a Zeiss
Axioplan microscope by the Animal Phenotyping Core Facility at the Rockefeller
University. For testicular analysis, seminiferous tubule diameters were measured and
interstitial cell numbers were counted under randomly selected 20X power field blind of
genotype. Macroorchidism was assessed by combined weight of both testes of I304N
knock-in mice compared to that of either wild type or Fmr1 knockout littermates.
Measurements from multiple litters of similar ages were pooled and subjected to
statistical analysis.

RNA preparation
RNA from mouse tissues or polyribosome fractions was both extracted using Trizol LS
Reagent (Invitrogen). 10ng luciferase RNA was spiked into each polyribosome fraction
as a control for RNA recovery. 49:1 chloroform:isoamyl alcohol was added to facilitate
aqueous and phenol-chloroform organic phase separation. After 15min 12,000xg
centrifugation, the aqueous phase where RNA remained was collected and precipitated
with ethanol at -20oC overnight. After precipitation, RNA was pelleted at 20,000xg for
20min at 4oC, washed with 75% ethanol, and then was dissolved in H2O. Extracted RNA
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was then RQ1 DNase (Promega) treated at 37oC for 1hr and underwent a second round of
phenol-chloroform extraction and ethanol precipitation.

Quantitative RT-PCR
Purified RNA was reverse transcribed using random hexamers (Roche) and superscript
III reverse transcriptase (Invitrogen). cDNA products were amplified using SYBR green
PCR master mix (Applied Biosystems) with 200nM of the following primers.
Fmr1 1F (spanning exon 2 to 3) 5’-TGAAAACAACTGGCAACCAGAGAG-3’
Fmr1 1R (spanning exon 2 to 3) 5’-CAGGTGGTGGGAATCTCACATC-3’
Fmr1 2F (spanning exon 10 to 11) 5’-GTCAGGAGTTGTGAGGGTGAGG-3’
Fmr1 2R (spanning exon 10 to 11) 5’-GGAAGGTAGGGAACTTGGTGGC-3’
GAPDH F 5’-CATGGCCTTCCGTGTTCCTA-3’
GAPDH R 5’-GCGGCACGTCAGATCCA-3’
Luc F 5’-GCCTTGATTGACAAGGATGGA-3’
Luc R 5’-CAGAGACTTCAGGCGGTCAAC-3’
Mtap1B F 5’-CATCACTGAACCACAGACTTGCG-3’
Mtap1B R 5’-AGCTGCCACTGAGAAGTTTGCC-3’
APC F 5’-TGAGAATACCGATGACAAACACC-3’
APC R 5’-CCACTGGTCCCCTTGACC-3’
Rab6ip F 5’-GTTCACCAACAGGGAACAGATG-3’
Rab6ip R 5’-GGGCAGGTAGGGCTCAGG-3’
Kif5c F 5’-GGAGGAGGAGGTGGCTCTTC-3’
Kif5c R 5’-GGGACAGAAAGGAACTGGTGAC-3’
Arhgap5 F 5’-CGCGCCGGGAGAGATG-3’
Arhgap5 R 5’-TGTAGTTCCCTCATTGCCAAAG-3’
Quantitative PCR amplification of was performed using 7900HT sequence detection
system (Applied Biosystems) at Genomic Resource Center at The Rockefeller University.
Fluorimetric intensity of SYBR green was monitored during each cycle of amplification
to quantify mRNA level. Regression curves were drawn for each sample and relative
amount of mRNA was calculated from the threshold cycles using the instrument’s
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software, SDS 2.0. For expression level in total brain, relative Fmr1 mRNA level was
measured using standard curve method and normalized to internal control GAPDH
mRNA. For polyribosome distribution, relative Fmr1 mRNA or FMRP target mRNA
level in each fraction was normalized to spiked in luciferase RNA analyzed using ΔΔCt
method. mRNA in each fraction was then plotted as a percentage of its total over the
entire polyribosome gradient to illustrate its translational profile.

Northern blot
Northern blot was performed following NorthernMax-Gly protocol (Ambion). Briefly,
30ug of brain RNA and 10ug of testes RNA were denatured by with Glyoxal load dye at
50oC for 30min and then were separated on a 0.8% agarose gel in 1X Gel Prep/Gel
Running buffer. The RNA then was transferred from the agarose gel to a GeneScreen
Plus hybridization transfer membrane (Perkin Elmer) in 10XSSC. P32-labeled Fmr1 probe
was hybridized to membrane at 68oC for 2hrs in QuikHyb hybridization solution
(Strategene). β-actin probe was hybridized at 42oC for 1hr with in Ultra-Hyb Oligo
solution (Ambion). Membrane was then washed with 2XSSC, 0.1% SDS and 0.1XSSC,
0.1% SDS at room temperature. Radiolabeled signals were detected and quantified by
phosophoimager (Bio-Rad).
Fmr1 probe, complementary to 3’UTR region, was synthesized by T7 in vitro
transcription with trace P32-α-UTP using Maxiscript Kit (Ambion). Template DNA for
transcription was generated using a reverse primer that had the T7 core promoter
sequence appended (underlined).
Fmr 3UTR F 5’-TCAGCAGTATGTTTCAGTCTTTCGG-3’
Fmr 3UTR R 5’TAATACGACTCACTATAGGGGAGAGTTTTCAAAGTTGAAATTCGTCATCAGG
-3’
20nt long DNA anti-sense to β-actin exon 4 was 5’ end radiolabeled with T4 PNK (NEB)
and used as Northern probe for β-actin.
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Antibodies
The following antibodies were used throughout this work:
mouse monoclonal anti-FMRP 1C3 (1:1000, IB). Chemicon.
mouse monoclonal anti-FMRP 2F5 (1:100, IB) (Gabel et al., 2004).
rabbit polyclonal anti-FMRP 17722 (1:500, IB). Abcam.
mouse monoclonal anti-FMRP 7G1-1 (1:100, IB, IP) (Brown et al., 2001; Ceman et al.,
2003b) (Developmental Studies Hybridoma Bank (DSHB), University of Iowa.
rabbit polyclonal anti-FXR1P ML13 (1:10,000, IB). A generous gift from Dr. E.
Khandjian (Université Laval).
mouse monoclonal anti-FXR2P 1G2 (1:100, IB). DSHB, University of Iowa.
mouse monoclonal anti-hsp90 (1:5000, IB). BD Bioscience.
mouse monoclonal anti-β-actin (1:20,000 IB) Abcam.
mouse monoclonal anti-γ-tubulin (1:10,000) Sigma.
mouse monoclonal anti-ribosomal S6 protein. Cell Signaling.
human POMA patient serum against Nova (1:1000, IB)
mouse monoclonal anti-His-tag HRP conjugated (1:5000, IB). Novagen.
mouse monoclonal N-APC antibody (1:500, IB) and rabbit polyclonal M-APC antibody
(1:500, IB). A generous gift from Dr. I. Nathke (University of Dundee).
mouse monoclonal anti-Kif1a (1:500, IB). BD Bioscience.
rabbit polyclonal anti-Kif5a (1:1500, IB). Affinity Bioreagents.
rabbit polyclonal anti-Akap6 (1:2000, IB). Abcam.
rabbit polyclonal anti-Grin2b (1:1000, IB). Covance.
mouse monoclonal anti-Psd95 (1: 1,000,000, IB). Upstate.
mouse monoclonal anti-Munc13 (1:200, IB). BD Bioscience.
mouse monoclonal anti-β-catenin (1:500, IB). BD Bioscience.
Mouse monoclonal anti-active β-catenin (1:1000, IB). BD Bioscience.
Mouse monoclonal anti-NMDAR1 (1:2000, IB). Chemicon.
Rabbit polyclonal anti-Synaptophysin (1:2000, IB). Chemicon.
Mouse monoclonal anti-CamKIIα (1:20,000, IB). Chemicon.
Rabbit polyclonal anti-Ago1 and Ago2 (1:250, IB). A generous gift from Dr. T. Tuschl,
(The Rockefeller University).
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secondary anti-mouse, rabbit, or human antibodies. Jackson Immunoresearch.

Total tissue extract
Tissues were each Dounce homogenized in RIPA lysis buffer (0.5% NP-40, 0.5%
deoxycholic acid, 0.1% SDS in PBS, 50% glycerol, and Complete protease inhibitor
cocktail (Roche)) sonicated, and spun 20,000xg at 4oC for 15min. Protein concentration
was determined by Bradford assay. 50ug of protein from each sample was boiled in SDSsample loading buffer and continued for Western analysis.

Western Analysis
Samples were run on SDS polyacrylamide gels and transferred onto nitrocellulose
membranes (Millipore). Membranes were blocked for 1hr at room temperature in 10%
non-fat milk in Western blot wash buffer (WBWB) (23mM Tris, pH 8.0, 190mM NaCl,
0.1% w/v BSA, 1mM EDTA, 0.5% Triton X-100, 0.02% SDS). Respective primary
antibodies

and

horseradish

peroxidase-labelled

secondary

antibodies

(Jackson

Immunoresearch) in 10% milk-WBWB were used during incubation from 1hr at room
temperature to overnight at 4oC. Blots were washed with WBWB 5min for 5 times after
each antibody incubation. Signals were detected by Chemiluminescence (Perkin Elmer)
and quantified with Versadoc Imaging System (Bio-Rad).

T7 transcription and directed UV crosslinking IP
96 nt long GQ and KC RNAs (Darnell et al., 2005a; Darnell et al., 2001) were generated
by T7 in vitro transcription of with P32-α-UTP and P32-α-GTP RNAs were ureapolyacrylamide gel purified and spiked into 100ul supernatant S2 brain lysate prepared as
for polyribosome analysis below. RNAs were incubated with the brain lysates for 15min
at room temperature and then UV crosslinked with Stratalinker. Lysates were then diluted
with RIPA buffer (0.5% NP-40, 0.5% deoxycholic acid, 0.1% SDS in PBS) to increase
the stringency for the following IP. IP was performed the same way as coimmunoprecipitation below, with the exception that RIPA buffer was the IP and wash
buffer. Immunoprecipitates were run on 4-12% SDS-PAGE, transferred to nitrocellulose
membrane, and exposed for autoradiograph.
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Co-immunoprecipitation of FMRP and FXRPs
1:1 slurry of protein A sepharose beads (Sigma) were first bound to 120ug of rabbit antimouse Fcγ bridging antibody (Jackson Immunoresearch) and then bind to 10ul of antiFMRP monoclonal 7G1-1 ascites (5mg/ml). Brain cytoplasmic lysates (0.5% Triton X100, 10mM Hepes, pH 7.4, 200mM NaCl, 30mM EDTA, Complete protease inhibitor
cocktail (Roche)) were incubated with beads and antibodies at 4oC for 2 hrs.
Immunoprecipitates were washed four times with the same lysis buffer to remove nonspecific binding. Proteins were eluted off the protein A-Sepharose beads by boiling in
SDS sample loading buffer and analyzed by Western analysis.

Mouse brain polyribosome analysis
Mouse brain polyribosomes were prepared according (Darnell et al., 2005a; Stefani et al.,
2004). Briefly, post-natal 2 week-old mice were sacrificed by decapitation. The brain was
removed and placed in ice-cold dissection buffer (10mM Hepes-KOH, pH 7.4, 150mM
KCl, 5mM MgCl2, 100ug/ml cycloheximide). Cortex and cerebellum were dissected free
of underlying white matter, homogenized in 1ml per cortex lysis buffer (10mM HepesKOH, pH 7.4, 150mM KCl, 5mM MgCl2, 0.5mM DTT, 100ug/ml cycloheximide, 1X
Complete EDTA-free protease inhibitor cocktail (Roche), 40U/ml rRNAsin (Promega))
with 12 strokes at 900rpm in a motor-driven glass-Teflon homogenizer. Homogenate was
spun at 2000xg for 10min at 4oC. The supernatant (S1) from the homogenized material
was collected and adjusted to 1% NP-40, v/v. After incubation for 5min on ice, S1 lysate
were spun at 20,000xg for 10min at 4oC and the supernatant (S2) was loaded onto a 2050% w/w linear density gradient of sucrose in 10mM Hepes-KOH pH 7.4, 150mM KCl,
and 5mM MgCl2. Gradients were ultracentrifuged at 40,000xg for 2hrs at 4oC in a
Beckman SW41 rotor. Fractions of 0.75ml volume were collected with continuous
monitoring at 260nm using ISCO UA-6 UV detector. Proteins in each fraction of sucrose
gradients were TCA precipitated and analyzed by Western blot.
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Superose 6 gel filtration
We used a pre-packed Superose 6 Precision column PC 3.2/30 in a SMART system (GE
Healthcare) to determine the molecular masses of protein complexes. The optimal
separation range of globular proteins in this column is 5kD to 5000kD with its exclusion
limit of 40,000kD. Mouse brain cytoplasmic lysates (0.3% NP-40, 10mM Hepes, pH 7.4,
150mM KCl, either with or without 30mM EDTA) were spun over a 0.22um Costa
SpinX column (Corning Incorporated) before loaded onto the Superose 6 column with a
flow rate of 30ul/min. Protein profile was monitored at A280nm and fractions of 75ul
were collected. Fractions were TCA precipitated for Western analysis. To calibrate the
column, protein markers (GE Healthcare) were run and gave the following results: blue
dextran (void ≥40,000kD) in fraction 4, thyroglobulin (669kD) in fraction 10 to 11,
ferritin (440kD) in fraction 13, albumin (67kD) in fraction 15, and ribonuclease (13.7kD)
in fraction 18. Molecular mass was extrapolated for each fraction according to the
migration of these protein markers and used for identification of protein complex sizes
we studied. For complete RNase digest, recombinant RNase A (Ambion) and T1
(Ambion) were added to mouse brain lysates to a final concentration of 20ug/ml and
10,000U/ml respectively. Lysates were incubated at room temperature for 30min before
gel filtration.

Behavioral analysis
Mice were derived from crosses between I304N/+ female and wild type male mice on
c57/b genetic background. All assays were done blind of the genotype essentially as
described (Peier et al., 2000; Spencer et al., 2006).

Electrophysiology
Hippocampal slices (400uM) were prepared from 30-90 day old I304N knock-in mice
and their wild type littermates bred to congenic C57bl/6 strain. All experiments were
performed blind of the genotypes. Extracellular field potentials (FPs) were measured in
the stratum radiatum of hippocampal CA1 elicited by Schaffer collateral stimulation.
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mGluR-LTD was induced by application of 100uM DHPG for 5min or by PP-LFS at 1Hz
for 20min, 50ms interstimulus interval. Synaptic strength was measured as the initial
slope (10-40% of the rising phase) of the FP. LTD magnitude was compared at 60-70min
after the onset of DHPG or PP-LFS. Independent t-tests were used to determine statistical
significance.

CLIP (in vivo Cross-link and Immunoprecipitation) method
FMRP CLIP and Argonaute CLIP were adapted from Nova CLIP (Ule et al., 2005a).
UV crosslinking of mouse brains
Cortex, cerebellum and hippocampus from P8 mice were harvested and sat in cold HBSS
(50ml 10X Hank’s balanced salt solution, Ca-Mg-free, (Invitrogen), 5ml 1M Hepes, pH
7.4, 445ml ddH2O) until harvest was complete. Tissues were triturated with a 5ml pipette
and resuspended in 10 volumes of HBSS. Suspension was irradiated using 10ml per
10cm tissue culture plate six times for 400mJ/cm2 in Stratalinker (Strategene model
2400). After irradiation, tissue suspension was collected and pelleted at 2500rpm 10min
at 4oC. Pellets were resuspended in HBSS (~2X pellet volume), distributed to Eppendorf
tubes (1 brain per tube), quick pelleted at 4oC. Pellets (~0.6ml/tube) were kept frozen at 80oC until needed.
Immunoprecipitation with anti-FMRP 7G1-1 antibody
For each tube of crosslinked lysate 400ul protein A dynabeads (Dynal) were used. Beads
were washed 3x with 0.1M Na-phosphate pH 8.0 and then were resuspended in 400ul of
same wash buffer with 50ul of rabbit anti-mouse Fcγ bridging antibody, 2.4mg/ml
(Jackson Immunoresearch), rotating at room temperature for 45min. After binding
bridging antibody, beads were again washed 3x with 0.1M Na-phosphate pH 8.0 and then
resuspended in the same buffer with 8ul of FMRP “specific” 7G1-1 antibody, 5mg/ml
rotating at 4oC over night. Antibody bound beads were washed 3x with 1XPXL (0.1%
SDS, 0.5% deoxycholate, 0.5% NP-40, PBS tissue culture grade, Ca-Mg-free).
Each tube of crosslinked brain bits was lysed with 700ul of 1XPXL with 1X Complete
EDTA-free protease inhibitor cocktail (Roche) and let sit on ice for 10min. 15ul RNAsin
(Promega) and 20ul of RQ1 DNase (Promega) were added to each tube and incubated in
Thermomixer R (Eppendorf) at 37oC for 5min, 1000rpm. 10ul of 1:10,000 dilution of
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RNase A, 5mg/ml (USB) was used to limiting digest RNA at 37oC fro 10min, 1000rpm.
Lysates were spun in pre-chilled ultra-microcentrifuge (polycarbonate tubes in TLA
120.2 rotor) at 30,000rpm for 20min at 4oC. Supernatants were carefully removed and
added to prepared tubes of beads for immunoprecipitation for 1.5hrs at 4oC. Beads were
washed with ice-cold buffer: 2x with 1XPXL, 2x with 5XPXL (0.1% SDS, 0.5%
deoxycholate, 0.5% NP-40, 5XPBS tissue culture grade, Ca-Mg-free) and 2x with
1XPNK (50mM Tris-Cl pH 7.4, 10mM MgCl2, 0.5% NP-40).
CIP treatment (on bead)
After immunoprecipitation, beads were resuspended in 80ul of 1X dephosphorylation
buffer and 3ul of calf intestinal alkaline phosphatase (CIP) (Roche) were added. Beads
were incubated in Thermomixer R at 37oC for 20min, programmed 1000rpm for 15sec
every 4min. Beads were washed with 1x with 1XPNK, 1x with 1XPNK/EGTA (50mM
Tris-Cl pH 7.4, 20mM EGTA, 0.5% NP-40) and 2x with 1XPNK.
Hot 3’ RNA linker ligation (on bead)
3’ RNA linker, L33 without 5’ phosphate, was 5’ radiolabeled with T4
phosphonucleotide kinase (PNK). 1ul of L33 no phosphate at 50pmol/ul, 15ul P32-γ-ATP,
6ul of T4 PNK (NEB), and 2ul RNasin (Promega) in PNK buffer (NEB) were incubated
at 37oC for 30min. The reaction was let go for additional 5min with 10ul 1mM ATP.
Radiolabeled 3’RNA was then spun through a G25 column (Amersham) to remove free
ATP. Each 10pmol of the labeled 3’ RNA linker were used for ligation reaction for one
tube of beads, in addition, 8ul of 10X T4 RNA ligase buffer (Fermentas), 8ul of BSA
(0.2ug/ul), 8ul 10mM ATP, 2ul T4 RNA ligase (Fermentas), 2ul of RNasin (Promega)
and H2O up to total volume of 80ul were added. On bead ligation reactions were
incubated at 16oC for 1hr at Thermomixer R programmed 1000rpm for 15sec every 4min.
After 1hr, 4ul of 3’RNA linker, L33 with 5’ phosphate at 20pmol/ul were added to each
tube of reaction and incubation was continued over night. The next day beads were
washed 3x with 1XPNK.
PNK treatment (on bead)
80ul of PNK mix (1ul 10mM ATP, 4ul T4 PNK enzyme (NEB), 2ul RNasin and 8ul of
10XPNK buffer (NEB), H2O up to 80ul) were added to each tube. Mixture was incubated
for 20min 1000rpm 15sec every 4min and washed 3x with 1XPNK.
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SDS-PAGE and transfer to nitrocellulose
Each tube of beads was resuspended in 13ul of LDS NuPAGE loading buffer
(Invitrogen), 4ul of 10X reducing agent (Invitrogen) and 13ul 1XPNK and incubated at
70oC for 10min at 1000rpm. Supernatant were taken off the beads for loading to Novex
NuPAGE 10% Bis-Tris gel (Invitrogen). After running at 175V for 3hr, the protein gel
was transferred to S&S BA-85 nitrocellulose using Novex wet transfer apparatus
(Invitrogen). After transfer, nitrocellulose was quickly rinsed with PBS, blotted with
Kimwipes, wrapped in plastic wrap and exposed to film.
Most of radiolabeled unligated L33 linker would run close with the gel front. Free RNA
ligated with L33 linker, which would have an average size of 70 nt, will migrate on the
gel mostly between 10-30kD. Using 1:10000 RNase A dilution would generate RNAs of
average size of 50 nt. As the tags contained 20 nt long L33 linker, their average size
would be 70 nt. Thus with our RNase A digest, FMRP-RNA complex would migrate on
average approximately 20kD higher than the molecular weight of FMRP alone due to the
bound RNA tags. Because RNase digestion is random, RNA tag sizes could vary from
30-150 nt, FMRP-RNA complex would therefore appear as a diffused radioactive smear.
Nitrocellulose membrane was aligned carefully with the exposed film and thin bands
approximately at 85, 90, 95 (ideal for FMRP-RNA complex), and 115kD (ideal for AgomiRNA complex) were cut out using a clean scalpel blade.
RNA isolation and purification
Each band of nitrocellulose membrane was further cut into smaller pieces and proteinase
K treated (200ul of 4mg/ml of proteinase K (Roche) in 1XPK buffer (100mM Tris-Cl pH
7.5, 50mM NaCl, 10mM EDTA)) at 37oC, 1100rpm for 20min. Then 200ul of 1XPK+7M
urea solution were added and incubated for another 20min at 37oC 1100rpm. Finally,
400ul RNA phenol (Ambion) and 130ul of 49:1 CHCl3:isoamyl alcohol were added and
incubated at 37oC, 1100rpm for additional 20min. Tubes were spun at 20000xg in
desktop microcentrifuge and aqueous phase is carefully taken. 0.5ul of glycogen
(Ambion), 50ul 3M NaOAc pH 5.2 and 1ml of 1:1 ethanol:isopropanol were added and
RNAs were precipitated overnight at -20oC.
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5’ RNA linker ligation
RNAs were spun down, washed; pellet dried and dissolved in 6ul H2O. RNA ligation was
performed with 1ul 10X T4 RNA ligase buffer (Fermentas), 1ul BSA (0.2ug/ul), 1ul ATP
(10mM), 0.1ul T4 RNA ligase, 3U (Fermentas), 1ul L51 RNA linker at 20pmol/ul and
6ul of RNA in H2O at 16oC overnight.
DNase treatment and RT-PCR
To the ligation reaction, 77ul H2O, 11ul 10X RQ1 DNase buffer, 5ul RQ1 DNase
(Promega) and 5ul RNasin (Promega) were added and incubated at 37oC for 20min.
300ul H2O, 300ul RNA phenol (Ambion) and 100ul CHCl3 were added, vortexed, spun
and aqueous layer taken. RNAs were precipitated with 50ul 3M NaOAc pH 5.2, 1ul
glycogen (Ambion) and 1ml 1:1 ethanol:isopropanol over night at -20oC. Next day,
RNAs were spun down, pellet was washed, dried, and resuspended in 8ul of H2O.
8ul of RNA were mixed with 2ul of P33 at 5pmol/ul, incubated at 65oC for 5min, chilled,
and spun. 3ul 3mM dNTPs, 1ul 0.1M DTT, 4ul 5X SuperScript RT buffer, 1ul RNasin,
and 1ul SuperScript III (Invitrogen) were added and incubated at 50oC for 30min, 90oC
for 5min and left at 4oC.
PCR reactions were performed with 27ul Accuprime pfx supermix (Invitrogen), 1ul P51
primer, 5pmol/ul, 1ul of P33 primer, 5pmol/ul and 2ul of the RT reaction, cycled 20-25
cycles with 95oC 20sec, 61oC 30sec, and 68oC 20sec.
Polyacrylamide gel separation of RNA
A 10% denaturing polyacrylamide was poured and the entire PCR reaction was run. 3ul
Amplisize Molecular Ruler (Biorad) were used. To visualize DNA, the gel was immersed
in 10000-fold dilution of SYBR Gold (Molecular Probes) in TBE for 10min. DNA of 60100 nts was cut out. DNA was extracted with Qiaex II kit (protocol for polyacrylamide
gel) (Qiagen) and resuspended in 15ul of H2O.
TOPO Cloning and sequencing
A overhang was generated by incubating 2.5ul DNA with 2.5ul Accuprime Taq Supermix
(Invitrogen) for 10min at 72oC in Thermomixer R. Cloning was done with 4ul DNA, 1ul
salt solution, and 1ul pCR4-TOPO vector (Invitrogen), which was incubated 5min at
room temperature and transformed into TOP 10 cells. Plasmids were isolated using DNA
mini-prep, and sequenced using the T7 primer.
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Concatamerization
Samples with good sequences (mouse sequences and ideal sized tags for FMRP, 50-70 nt
long inserts) were concatermized and sequenced on a larger scale. 3ul Qiaex II purified
RT-PCR DNA were amplified using 95ul Accuprime pfx supermix (Invitrogen) and 1ul
P51BanIa, 100pmol/ul and 1ul P33BanI 100pmol/ul, cycled 15 cycles with 95oC 20sec,
61oC 30sec, and 68oC 20sec. PCR product was extracted using 200ul DNA
phenol/chloroform (Sigma), then 200ul 24:1 chloroform:isoamyl alcohol. Aqueous
fraction was collected and DNAs were precipitated by add 14ul 5M NaCl (0.1M final)
and 500ul ethanol (2.5 volume) at -20oC over night. DNAs were pelleted, washed, dried
and resuspended in 80ul of 1X NEBuffer 4 (NEB) and 4ul of Ban I enzyme (20U/ul)
(NEB) were added; DNAs were digested at 37oC for 3hr. Then DNAs were
phenol/chloroform (Sigma) extracted and ethanol precipitated. Pellet was resuspended in
66ul of H2O, 8ul 10X T4 DNA ligase buffer (NEB), 1.2ul P51BanIa, 100pmol/ul, 1.2ul
P33BanIa 100pmol/ul were added. Before adding ligase, the reaction was incubated at
65oC for 10min and chilled on ice immediately, in order to quench short cleaved ends to
prevent re-ligation. Then 4ul T4 DNA ligase (2000U/ul) (NEB) were added and
incubated at 16oC over night. The next day, 1ul of T4 DNA ligase was added to let the
reaction continue for an additional hour. The reaction was desalted on G-25 column
(Amersham) and run on a 2% low melting (NuSieve) agarose gel. Concatemer products
were purified using Qiaex II (Qiagen) and TA cloned and sequenced.
Linker and primer sequences
RNA linkers (from Dharmacon):
R51: 5’-OH AGG GAG GAC GAU GCG G 3’-OH
R33: 5’-P CGG UUG CGA GGU GAG UGA A 3’-puromycin
R33 no P: 5’-OH CGG UUG CGA GGU GAG UGA A 3’-puromycin
DNA primers (from Operon):
P51: AGGGAGGACGATGCGG
P33: CTTCACTCACCTCGCAACCG
Concatermization primers:
P51BanIa: CAGCCAACAGGCACCAGGGAGGACGATGCGG
P33BanIa: CACTAGCTTGGTGCCTTCACTCACCCTCGCAACCG
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Synaptoneurosome preparation (filtration method)
We used filtration method for synaptoneurosome preparation from mouse brains
(Ceman et al., 2003b; Shin et al., 2004). Cortex and hippocampus were dissected in cold
PBS free of underlying white matter. Tissue was immediately Dounce homogenized in
2ml of ice cold buffer ((10mM Hepes pH 7.4, 2mM EDTA, 2mM EGTA, 0.5mM DTT,
100mM sucrose, and Complete protease inhibitor cocktail (Roche), detergent free).
Homeogenate was filtered sequentially through two 100 micron nylon mesh filters (Small
Parts, Inc.); and filtrate centrifuged at 2000xg for 1min at desktop centrifuge. Supernatant
was collected and passed through a 5 micron pore filter (Millipore) and filtrate was
centrifuged at 1000xg for 10min. The pellet was resuspended in SDS sample loading
buffer for Western blot analysis.
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CHAPTER III. GENERATION AND
CHARACTERIZATION OF I304N MOUSE MODELS FOR
FRAGILE X SYNDROME
Introduction
Fragile X mental retardation, the most common form of inherited mental
retardation, presents with a clinical picture of moderate to severe mental retardation,
macroorchidism, seizures, connective tissue dysplasia, and complex behavioral and
cognitive deficits. In most cases, the disease is caused by transcriptional silencing of the
fragile X mental retardation 1 (Fmr1) gene as a result of CGG repeat expansion and
hypermethylation of CpG islands in the 5’UTR region (O'Donnell and Warren, 2002).
Multiple functional domains have been characterized in the Fragile X mental retardation
protein (FMRP). These include two tandem KH-type RNA binding domains (named for
their homology to hnRNPK) (Siomi et al., 1994; Siomi et al., 1993b), an arginine and
glycine-rich RNA binding domain (RGG box) (Siomi et al., 1993b), and an N-terminal
domain (NDF), similar to Tudor/Agenet domains, that may be involved in both RNA
binding and protein-protein interactions (Adinolfi et al., 2003; Mazroui et al., 2003;
Ramos et al., 2006; Zalfa et al., 2005).
The presence of multiple functional domains within FMRP has made it difficult to
determine which lost functions are sufficient for causing Fragile X Syndrome. A single
severely affected patient with a missense mutation in FMRP has offered hope of focusing
FMRP studies in a key functional domain. This patient has severe mental retardation with
IQ measured below 20 and impressive macroorchidism with both testes exceeding 100ml
volume (DeBoulle et al., 1993). The patient harbors a single nucleotide mutation in a
conserved isoleucine, changing it to an asparagine (I304N), within the KH2 domain.
Our interest in FMRP, and this I304N mutation in particular, arose from studies of
a structurally related neuronal RNA binding protein termed Nova (Darnell, 2006). Nova
harbors three RNA binding domains with a similar spacing to those in FMRP—two
paired (tandem) KH domains, intervening sequence, and a third KH domain (Burd and
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Dreyfuss, 1994; Lewis et al., 1999). The RNA binding specificity of Nova’s KH domains
have been well defined, including determination of the structure of one Nova KH domain
co-crystallized with its RNA ligand (Lewis et al., 2000). This study revealed that Nova
binds RNA in a sequence-specific manner, using amino acid side-chains to precisely
coordinate two nucleotides (CA) in the midst of a pyrimidine-rich region. This binding
pocket is supported by three conserved hydrophobic amino acids, one of which, a leucine,
is found to be the corresponding amino acid to the isoleucine in the I304N FMRP
mutation (Lewis et al., 2000; Ramos et al., 2003).
Extrapolating the results from Nova to FMRP, these results suggest the possibility
that the key defect in FMRP loss-of-function is the loss of sequence-specific RNA
binding, mediated through the FMRP KH2 domain, and requiring isoleucine-304 in
particular. This interpretation has been complicated by questions of whether such a
mutation might lead to an unfolded protein and the loss of other functions of the protein
in addition to RNA binding, as analogous mutations in vigilin KH6, Nova KH3, FMRP
KH1 (Lewis et al., 1999; Musco et al., 1997; Musco et al., 1996) have been reported to
result in the complete unfolding of the domain. Other KH domains remain well structured
with this mutation including SF1 and dFXR KH1-KH2 (Liu et al., 2001; Pozdnyakova
and Regan, 2005; Ramos et al., 2003), yet specific RNA binding is lost. Here we address
these issues by generating and analyzing mouse models harboring the I304N mutation.
We will examine whether the mouse models support the production of I304N FMRP,
whether the mutant protein is completely denatured or still retains some functions, and
whether this point mutation in FMRP KH2 domain causes loss of RNA binding, as we
may have predicted. Lastly, we will assess whether I304N mouse models phenocopy the
Fragile X Syndrome.

Results
Generation and general description of Fmr1 I304N mice
Two mouse models were generated to phenocopy the I304N patient. Initially we
generated BAC transgenic mice harboring the I304N mutation (Figure 3.1). BAC
transgenic technology has several advantages over conventional transgenics (Yang et al.,
1997). First, BAC trangenes are present on a large piece of DNA, when they insert in the
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genome, they are relatively immune from positional effects caused by the neighboring
sequences. Second, BAC transgenes include the most distal enhancers and all intronic
elements. They are spliced and regulated like the endogenous gene, which is a huge
improvement over traditional cDNA transgenics. At the time, when our Fmr1 BAC
transgene was obtained, it was the only one available (Musunuru, K, PhD thesis). It is
unfortunate because the BAC gene is so close to the 5’ end Fmr1 gene that it is no better
(but also no worse) than a traditional transgene in terms of positional effects, therefore
we need several lines of transgenic mice, just as for a traditional transgene. Two lines of
I304N BAC transgenic mice and one control line of wild type Fmr1 BAC transgenic mice
were obtained and bred to the FVB Fmr1-null background. Despite their considerable
advantages over traditional transgenics, BAC transgenic mice have at least one potential
drawback, which is gene dosage variability, as they tend to incorporate in the genome as
tandem repeats. We were only able to generate three lines of mice despite several
attempts at injection, perhaps because overexpression of FMRP is toxic to the nervous
system. Therefore, we may have selected for mice with lower expression in brain due to
positional effects.
At this point it was unlikely for us to generate multiple lines of I304N and wild
type control BAC transgenic mice to properly control for gene dosage and positional
effects in our BAC transgenics. Therefore, we generated a second and “cleaner” mouse
model, the I304N knock-in (KI) mouse, using conventional gene targeting (Figure 3.2A).
An Fmr1 KH2 I304N targeting cassette, including a self-excising loxP-Auto-Cre-NeoRloxP (ACNF) cassette (Bunting et al., 1999) was electroporated into ES cells and 53
homologous recombinants were identified by Southern blot (Figure 3.2B). Germline
chimeras were bred to generate I304N knock-in male mice. These mice were backcrossed
ten generations into both FVB and C57/BL6 backgrounds. As we were successful in
knocking in this mutation by homologous recombination most of our subsequent analysis
focused on the I304N knock-in mice. I304N BAC transgenic mice were used when
appropriate to support the findings in the knock-in model.
I304N knock-in mice were viable and did not exhibit an overt phenotype. Mutant
mice were fertile with normal litter sizes, and transmitted the mutant allele in an X-linked
Mendelian pattern (data not shown). Histological examination of heart, spleen, liver,
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lung, kidney, adrenal glands, stomach, intestines, muscles, diaphragm, bladder, thymus of
I304N KI mice revealed no abnormalities (data not shown). We especially focused on the
brain and testes, as both organs are functionally and anatomically abnormal in fragile X
patients, and the I304N patient in particular. The cerebellum (Figure 3.3A, B, C and D),
cortex (Figure 3.3E, F, G and H) and hippocampus (Figure 3.3I, J, K and L) of I304N
knock-in mice were macroscopically and microscopically normal. Microscopic
examination of testes of the I304N mouse revealed no structural difference compared
with wild type mice (Figure 3.3M, N, O and P). Macroorchidism is present in more than
90% of adult males with Fragile X Syndrome, and is particularly severe in the I304N
patient whose testicular volume exceeds 100 ml (DeBoulle et al., 1993). Fmr1 knockout
mice also exhibit progressively more severe macroochidism with age; their testicular
weights are up to 30% heavier than wild type mice at 6 months, the oldest age measured
(Dutch-Belgian Fragile X Consortium, 1994). Consistent with these observations,
testicular weights of adult I304N knock-in mice were found to be 15-30% heavier than
those of their wild type littermates, with the most pronounced difference seen at the
oldest age group (Figure 3.4A, B and E). Because the human I304N patient has a much
more severe macroorchidism than most Fragile X patients whose disease results from loss
of expression of FMRP, we compared the testicular weights of I304N knock-in mice and
Fmr1 knockout littermates. We found that they were not significantly different in mice up
to 600 days old. (Figure 3.4C, D, and E). There was no significant difference in body
weights between I304N knock-in mice and wild type or Fmr1 knockout littermates
(Figure 3.5).

I304N mRNA and protein expression
We examined the expression level of Fmr1 mRNA in I304N knock-in mice.
Northern blot and quantitative RT-PCR analysis showed that I304N Fmr1 mRNA was
expressed at wild type levels in both brain and testes (Figure 3.6A and B). The I304N
mRNA appeared to be of the correct size in both brain and testes, compared with wild
type littermates and in agreement with previous work (Ashley et al., 1993a; Pieretti et al.,
1991). Sequencing of RT-PCR products from the I304N mouse confirmed the correct
sequence of the introduced mutation (Figure 3.6C).
32

Western blot analysis was used to compare I304N protein expression in the brain,
testes, liver, and spleen with wild type levels at different post-natal ages. At 2 months of
age, I304N FMRP was expressed at ~50% of the normal level in brain (Figure 3.7A) and
remained at ~50% in brain at 6 months of age (Figure 3.7B). We noted that in younger
mice (P14), I304N was expressed at lower levels (~20% of the wild type level in brain;
Figure 3.8). For this reason, behavioral analyses and electrophysiologic studies of the
I304N mice were done in adults. Outside the brain I304N FMRP was expressed at
somewhat lower levels as well--~30% in testes, ~30% in spleen at 2 months of age
(Figure 3.7A) and ~40% in testes, ~90% in spleen, 70% in liver at P14 (Figure 3.8A and
B). Interestingly, expression levels of FXR1P and FXR2P, autosomal paralogs of FMRP,
did not increase to compensate for the low I304N protein levels (Figure 3.9).
To further address the variable protein levels in I304N relative to WT mice, we
also analyzed BAC transgenic mice harboring either I304N or wild type FMRP.
Transgene expression was studied by Western blot and quantitative RT-PCR. One line of
the I304N transgenic mice (TG I304N-B) expressed normal levels of the mutant protein
in adults (Figure 3.10A). However, analogous to the knock-in mice, at P14, there was
roughly a 4 fold decrease of I304N protein relative to mRNA in two lines of the I304N
BAC transgenic mice, but not in wild type Fmr1 BAC transgenic mice (Figure 3.10B).
These consistent findings, in both the knock-in and transgenic mice, together with similar
data in Drosophila harboring an analogous I307N mutant protein (Banerjee et al., 2007),
suggest that post-transcriptional regulation may lead to reduced levels of the mutant
I304N protein.
Decreased protein expression with normal mRNA levels suggests that I304N
FMRP may have either a slower protein synthesis rate or a faster protein turnover rate in
the mouse brain. We analyzed the I304N translational profile by examining its mRNA
distribution on polyribosome sucrose gradients compared with wild type littermates.
Quantitative RT-PCR of RNA from different fractions showed that I304N Fmr1 mRNA
had a similar distribution on polyribosomes to wild type Fmr1 mRNA (Figure 3.11).
These observations suggest that lower I304N expression is not likely due to translational
regulation, but may instead relate to increased turnover of the mutant protein.
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I304N FMRP retains some RNA and protein binding activities
In vitro RNA selection studies have identified a kissing complex RNA that is
bound with high affinity by the FMRP KH2 domain (Darnell et al., 2005a). Recombinant
I304N protein produced in bacteria has been shown to be competent to bind G-quartet
RNA, the high affinity RNA ligand for the RGG box of FMRP (Brown et al., 2001;
Darnell et al., 2001; Schaeffer et al., 2001), but not the kissing complex RNA (Darnell et
al., 2005a). We examined endogenous I304N protein in mouse brain to see whether it
would mimic these RNA binding abilities. Radiolabeled G-quartet or kissing complex
RNA was spiked into mouse brain lysates, UV-crosslinked, and immunoprecipitated with
FMRP antibody. When samples were run on SDS-PAGE gels, a radiolabeled
FMRP:RNA complex was seen specifically in the immunoprecipitate of the I304N
extract crosslinked to the G-quartet RNA, but not the kissing complex RNA (Figure
3.12A and B). When compared with the wild type, the reduced radioactive signal from
G-quartet RNA crosslinked to the I304N extract was consistent with the lower I304N
protein level in the knock-in mice (Figure 3.12C). Point mutations in G-quartet or
mutant kissing complex RNAs, which are not bound by recombinant I304N FMRP in
vitro (Darnell et al., 2005a; Darnell et al., 2001) also did not crosslink to either wild type
or I304N FMRP in mouse brains (data not shown).
We also evaluated whether the I304N FMRP was competent to interact with its
known protein partners. In vitro studies indicate that I304N FMRP is able to
heterodimerize with FXR1P and FXR2P (Laggerbauer et al., 2001a; Zhang et al., 1995)
and we analyzed these interactions in the brains of I304N knock-in mice. Coimmunoprecipitation from mouse brains confirmed that I304N binds in vivo to FXR1P
and FXR2P (Figure 3.13), demonstrating that I304N FMRP has an intact protein-protein
interaction domain. Taken together, these data indicate that the I304N protein in mouse
brain retains some normal activities, as it is competent to bind both protein and, via its
RGG-domain, to bind G-quartet RNA. Therefore the defect in the I304N protein may be
selective for defective KH2:sequence-specific RNA binding.
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I304N FMRP is dissociated from polyribosomes
The laboratories of Warren and Khandjian have provided the first evidence that
FMRP is on polyribosomes (Corbin et al., 1997; Feng et al., 1997a; Khandjian et al.,
1996) suggesting a role in translational regulation of specific mRNAs. , Significantly, in
I304N patient lymphoblastoid cells, mutant FMRP no longer associates with
polyribosomes (Feng et al., 1997a). Transfected reporter constructs also suggested that
the I304N mutation inhibits the ability of FMRP to associate with polyribosomes (Darnell
et al., 2005b). We examined whether the I304N mutation affected endogenous FMRPpolyribosome association in brain (Feng et al., 1997b; Khandjian et al., 2004; Stefani et
al., 2004). Polyribosome profiles were identical for wild type and I304N mouse brain
extracts (Figure 3.14A), indicating comparable global translation status. Similar to
previous findings in the patient lymphoblastoid cells as well as I304N FMRP- transfected
neuronal cell lines (Darnell et al., 2005b; Feng et al., 1997a), I304N FMRP was largely
dissociated from polyribosomes in mouse brain (Figure 3.14A and B). A negligible
amount of wild type FMRP was present in fractions lighter than 80S monoribosomes
(fractions 1-5) and more than 55% was on the very heavy polyribosomes (fractions 9-12),
while 44% of total I304N FMRP was in the corresponding light fractions and only 24%
on the polyribosomes. This result was further confirmed using I304N-FMRP transgenic
mice bred to the Fmr1 null background. One line of I304N BAC transgenic mice (TG
I304N-B) expressed the mutant protein at normal level in adult brain (Figure 3.10A) and
its polyribosome association was significantly decreased as well (Figure 3.15), indicating
that lack of polyribosome association is independent of steady state protein level, but
specific to the mutation. Also consistent with previous findings in patient lymphoblastoid
cell lines (Feng et al., 1997a), the I304N mutation in FMRP does not affect FXR1P or
FXR2P polyribosome association in mouse brain (Figure 3.14A).

I304N FMRP complex is abnormally small due to a loss of RNA binding
It has been suggested that the I304N mutation renders the protein incapable of
forming normal mRNP particles (Feng et al., 1997a). We analyzed endogenous I304N
particle size in brain by Superose 6 gel filtration of mouse brain cytoplasmic extracts.
Wild type FMRP was found in the void volume of the Superose 6 column, indicating that
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FMRP is normally associated with an mRNP of greater than 40,000 kDa (Figure 3.16A).
On the contrary, the vast majority of I304N FMRP was found in an abnormally small
complex eluting with standards of approximately 150-300 kDa (Figure 3.16B), which
correlated well with <440 kDa observed with patient lymphoblastoid cells (Feng et al.,
1997a).
To assess whether this small complex containing I304N might result from a loss
of protein-RNA interaction (Lewis et al., 2000; Liu et al., 2001; Ramos et al., 2003)
versus protein-protein interactions (Feng et al., 1997a; Laggerbauer et al., 2001a), we
treated brain cytoplasmic extract with excess RNase and then repeated Superose 6 gel
filtration. Under these conditions, the wild type FMRP mRNP apparent size was reduced
to the size of I304N complex (Figure 3.16C), while this RNase treatment did not further
alter the size of the I304N complex (Figure 3.16D). This data suggests that the I304N
FMRP in mouse brain has lost majority of its ability to associate with RNA. This likely
explains the dissociation of I304N mutant FMRP from polyribosomes.
We further examined the nature of the I304N complex by comparing its size with
denatured, recombinant His-tagged I304N protein added to mouse brain extract and sized
by Superose 6 gel filtration. Mouse brain I304N FMRP was found in a complex
significantly larger than the His-tagged I304N monomer (Figure 3.17) suggesting that
interactions with other proteins (most likely homodimerization with itself or
heterdimerization with FXR1P and FXR2P) are intact. These data and the finding that the
I304N protein coprecipitates with FXR1P and FXR2P demonstrate that I304N FMRP is
still capable of protein:protein interactions while most if not all of its RNA-binding
capacity is lost. This suggests that the loss of polyribosome association is due primarily
to a loss of RNA binding due to the I304N mutation in the KH2 RNA-binding domain.

I304N knock-in mice show similar behavior to Fmr1 knockout mice
I304N knock-in male mice and wild type littermates were subject to a battery of
behavioral assays, which included locomotor activity, anxiety related responses,
sensorimotor gating, learning and memory, analgesia, obsessive-compulsive activity, and
audiogenic seizure. Results of I304N knock-in mice were compared with historical
findings on Fmr1 knockout mice (Brennan et al., 2006; Kooy, 2003; Peier et al., 2000;
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Spencer et al., 2005; Spencer et al., 2006) in the same genetic background ad hoc
(Brennan et al., 2006; Kooy, 2003; Peier et al., 2000; Spencer et al., 2005; Spencer et al.,
2006). These experiments were performed by our collaborator Dr. Richard Paylor and the
results are summarized in Figure 3.18M.
Locomotive activity in an open field. A single mouse was placed in the open-field
arena and its activity was recorded over a period of 30min. I304N knock-in mice traveled
a greater total distance in the open field compared with their wild type littermates (Figure
3.18A), suggesting that I304N knock-in mice had increased exploratory behavior, similar
to Fmr1 knockout mice (Peier et al., 2000). There was no difference between I304N and
wild type mice for rearing, as measured by vertical activity (Figure 3.18B).
Anxiety related responses. The center:total distance ratio in the open field test is a
measurement of anxiety related response to a brightly-lit open arena. Wild type mice
preferred to stay along the perimeter of the arena while I304N knock-in mice traveled a
greater proportion of their distance in the center of the open field (Figure 3.18C). Light
and dark exploration test is another anxiety response test. Mice were allowed to move
freely between a large, open, and brightly lit chamber and a small, closed and dark
chamber. I304N knock-in mice exhibited a greater number of light-dark transitions than
their wild type littermates (Figure 3.18D). Both tests indicated that I304N knock-in mice
had a lower level of anxiety, like Fmr1 knockout mice (Peier et al., 2000). No difference
was observed between I304N knock-in and wild type littermates for the total time spent
in the dark (Figure 3.18E).
Startle habituation. Prepulse inhibition (PPI) of the acoustic response was used to
measure sensorimotor gating. A weak non-startling sound presented immediately before a
startling sound will suppress the startle response of an animal. I304N knock-in mice
exhibited significantly lower startle responses than their wild type littermates (Figure
3.18F), analogous to Fmr1 knockout mice (Peier et al., 2000; Spencer et al., 2006). As
the prepulse level increases, there is greater suppression of the startle response. There
was no significant difference in PPI between I304N knock-in mice and their wild type
littermates (Figure 3.18G), although Fmr1 knockout usually showed increased PPI
(Paylor, R unpublished data). This was one of the very few discrepancies of I304N and
Fmr1 knockout mice amongst a whole collection of behavioral tests.
37

Conditioned fear. Conditioned fear test, based on a Pavlovian learning and
memory paradigm, was used to examine cognitive functions. In the context test, mice
were given two mild foot shocks in a chamber, and 24 hours later they were placed back
in the same chamber and their freezing bouts as an index of fear were measured for 5min.
In the auditory conditioned stimulus (CS) test, mice were trained to associate an auditory
cue, conditioned stimulus (CS), with an aversive unconditioned stimulus (US), foot
shocks. 24 hours later mice were place in a novel chamber, but given the auditory cue
(CS) and their freezing bouts were measured. As observed in Fmr1 knockout mice,
I304N knock-in mice displayed no difference of conditioned fear in either context test or
auditory CS test compared with wild type littermates (Figure 3.18H and I) (Peier et al.,
2000; Spencer et al., 2006).
Hotplate. The hotplate test provides an assessment of sensitivity to pain. Mice
were placed on a 55oC hotplate and the latency of their first hindlimb response was
recorded. I304N knock-in mice showed a greater latency to hindlimb response than wild
type mice (p=0.076) (Figure 3.18J), suggesting they are less sensitive to pain, similar to
Fmr1 knockout mice (Paylor, R unpublished data).
Marble bury. Marble burying tests for obsessive-compulsive behavior and
perseveration. I304N knock-in mice buried more marbles than their wild type littermates
(Figure 3.18K), although Fmr1 knockout mice tended to bury less marbles (Paylor, R
unpublished data).
Audiogenic seizure. On C57BL/6 genetic background, 18% of I304N knock-in
mice showed audiogenic seizure (Figure 3.18L), unlike wild type or Fmr1 knockout
mice, none of which were susceptible to audiogenic seizure (Paylor, R unpublished data).
With the exception of these few discrepancies, these data suggest that I304N
knock-in mice are very similar to Fmr1 knockout mice in the majority of behavioral
assays.

I304N knock-in mice have altered synaptic plasticity in hippocampus
Metabotropic glutamate receptor dependent long term depression (mGluR-LTD)
in hippocampal CA1 area is a form of synaptic plasticity that relies on dendritic protein
synthesis. Previous work has shown that mGluR-LTD was enhanced in Fmr1 null mice
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(Huber et al., 2002) and that it no longer required de novo protein synthesis (Nosyreva
and Huber, 2006). We investigated the protein synthesis requirement for both chemically
induced (100uM 3,4-dihydroxyphenylglycine (DHPG), 5min) and synaptically induced
[using paired pulse low frequency stimulation (PP-LFS)] mGluR-LTD in acute
hippocampal slices prepared from I304N knock-in mice and their wild type littermates.
These experiments were performed by Dr. Kim Huber and colleagues using paired
littermates supplied by our lab. Pre-incubation with the protein synthesis inhibitor
anisomycin (20uM) inhibited both DHPG- (p=0.02) and PP-LFS- (p=0.004) induced
LTD in wild type mice as expected (Figure 3.19A and C). In contrast, anisomycin had
no effect on either form of LTD in I304N knock-in mice (Figure 3.19B and D), as
observed in Fmr1 knockout mice (Nosyreva and Huber, 2006). Our data suggests that the
I304N KI mice are similar to Fmr1 knockout mice in that in both, in contrast to wild type
mice, mGluR-LTD is no longer dependent upon new protein synthesis.

Discussion
Fragile X Syndrome presents with a clinical picture of moderate to severe mental
retardation and behavioral abnormalities including autistic features resulting from the loss
of function of an RNA-binding protein, FMRP. Although the disease is usually caused by
a triplet repeat expansion in the 5’UTR of the Fmr1 gene leading to loss of transcription
of Fmr1 mRNA, one severely affected patient has a point mutation in KH2 RNA binding
domain of FMRP (DeBoulle et al., 1993). This isoleucine to asparagine mutation (I304N)
has previously been shown by our lab and others to abolish RNA binding by this and
similar KH-type RBDs. Symptoms of Fragile X Syndrome in this patient therefore
suggest that the disease is caused by loss of sequence-specific RNA binding by this KH
domain in FMRP. However, it has not been formally demonstrated that this point
mutation caused Fragile X symptoms in this individual, as his clinical picture is
complicated by an unrelated familial liver disease.
To address this issue, we have generated and analyzed mouse models harboring
the I304N mutation. We find that the protein is present, albeit at somewhat reduced levels
in adult mice. It retains some normal activities, as it is competent to bind both protein
partners such as FXR1 and FXR2 and, via its RGG-domain, to G-quartet RNA. However,
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it is defective in polyribosome association and RNA binding. These findings, together
with FMRP null-like behavioral deficits and altered synaptic plasticity seen in the I304N
mouse, suggest that loss of RNA binding by the second KH domain contributes to the
dysfunctions underlying the Fragile X Syndrome.

I304N mutant protein is present, albeit at a lower level
Our genetic engineering of the I304N knock-in mouse model has been made such
that an Auto-Cre-NeoR (ACNF) cassette was inserted in a non-conserved region of Fmr1
intron 10 and it was entirely excised during spermatogenesis in male chimeric mice. Only
one loxP site remains in the Fmr1 intron of the I304N knock-in mouse, which does not
affect I304N Fmr1 mRNA transcription or splicing, as the mRNA is expressed at the
correct length and normal level. We have mutated ATT that corresponds to isoleucine304 to AAC to encode asparagine, a commonly used codon in mouse with a usage
frequency of 20.7% that is comparable to the 15.6% frequency of the ATT (Ile) codon.
Wobble mutations of CTG (Leu) to CTT (Leu) and CAA (Gln) to CAG (Gln) have been
made for the amino acid residues leucine and glutamine before and after the I->N
mutation. Mutated codons are also common codons with a comparable usage frequency
as the original codons in mouse.
The production of endogenous I304N mutant protein has been rigorously assessed
using multiple antibodies against FMRP. The protein is present in all tested tissues, albeit
at lower levels than in wild-type littermates. The post-transcriptional reduction in steady
state levels of I304N protein compared with mRNA levels has not only been observed in
I304N knock-in mice, both lines of I304N BAC transgenic mice, but also in I307N dFXR
flies (Banerjee et al., 2007), suggesting that it is intrinsic to the mutation rather than a
result of our genetic manipulation. Lower steady state levels of I304N FMRP in brain and
testes is surprising in light of previous data demonstrating that I304N FMRP is expressed
at normal levels in the patient, as detected using EBV transformed patient lymphoblastoid
cells (Feng et al., 1997a). Reasons for the differences between our findings and
previously published data are that immortalized cell culture systems do not necessarily
mimic the context of the endogenous protein in a living organism, and that the we also
detect relatively normal levels of I304N expression in some tissues. Therefore, I304N
40

FMRP levels may be normal in the patient’s primary blood cells (a clinically unaffected
tissue) as well,. In light of these findings it would be interesting to assess FMRP levels in
the patient’s nervous system, but not feasible.
I304N Fmr1 mRNA has a normal translational profile on polyribosomes,
suggesting its low protein levels is not likely due to translational repression. This is an
issue of interest because it has been reported that FMRP can bind a G-quartet in the
coding sequence of its own mRNA, possibly inhibiting its translation (Schaeffer et al.,
2001). Our genome wide screen for FMRP RNA targets has not identified its own mRNA
as a target (see Chapter IV). We hypothesize the observed low protein level is due to
faster turnover of the mutant protein.

I304N FMRP retains some characterized functions
Structural biologists have studied the I304N mutation in many similar KH-type
RBDs. Vigilin KH6, FMRP KH1, and Nova KH3 (Lewis et al., 1999; Musco et al., 1997;
Musco et al., 1996) are completely unfolded as judged by circular dichroic spectroscopy,
while SF1 and dFXR KH1-KH2 (Liu et al., 2001; Pozdnyakova and Regan, 2005;
Ramos et al., 2003) are correctly folded. Structural studies using recombinant proteins
cannot definitively prove the outcome of I304N folding in vivo. These contradictory
findings make it difficult to determine the direct cause of the patient’s disease, whether it
is due to a denatured and completely functionless I304N protein or due specifically to the
lack of KH2 domain-mediated RNA binding.
We have shown that mouse brain I304N protein retains its ability to bind Gquartet RNA via its C-terminal RGG box (Darnell et al., 2001) and its ability to
heterodimerize with FXR1P and FXR2P, mediated by its N-terminal domain (Adinolfi et
al., 2003; Mazroui et al., 2003; Ramos et al., 2006). These functional assays prove to us
I304N protein in mouse brain is not a completely denatured functionless protein, but
retains some normal activities. While I304N protein still binds G-quartet RNA, it has lost
binding to kissing complex RNA (Darnell et al., 2005a), suggesting the defect in the
I304N protein is selective for KH2 sequence specific RNA binding. In vitro ligand
binding experiments support our mouse model, since a previously known dysfunction of
the I304N protein is observed in these mice. Concurrently we have demonstrated that the
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in vitro-selected RNA motifs previously characterized with I304N FMRP produced from
bacteria and baculovirally infected insect cells, are indeed bound by endogenous brain
FMRP.

I304N FMRP is defective in polyribosome association and RNA binding
We have confirmed previous findings that vast majority of I304N protein is
dissociated from polyribosomes in mouse brain (Darnell et al., 2005b; Feng et al., 1997a).
In addition to showing that I304N FMRP no longer binds kissing complex RNA, we also
show that I304N FMRP is in a 150-300 kDa complex in mouse brain, and that is not
reduced in size after treatment with RNases, suggesting it has lost RNA binding. In
contrast, the wild type FMRP mRNP is >40,000 kDa in size and after RNase treatment, it
decreases to the size of the I304N complex. All these data suggest to us that loss of RNA
binding due to the I304N mutation in the KH2 domain is likely to be the primary cause
for polyribosome dissociation, thus loss of correct translational control.
Here we have reported two seemingly contradictory findings—the I304N FMRP
protein is capable of binding G-quartet RNA, but it is found mostly in an RNase resistant
complex. One possibility is that FMRP may bind differently to endogenous than to
SELEX ligands, which usually are the highest affinity binders. RBPs are usually
composed of multiple combinations of just a few basic domains and these domains can
function together in various ways to achieve specificity and affinity that is not possible
for a single domain or if the domains did not cooperate (Lunde et al., 2007). Since an
RGG box mutation does not affect FMRP polyribosome association (Darnell et al.,
2005b; Mazroui et al., 2003), we hypothesize that the binding of FMRP to endogenous
RNAs may require a hierarchical binding of the KH2 domain before the RGG box. When
two RBDs are separated by a flexible spacer, after the first domain binds RNA, the
second domain can just sweep within the sphere of the spacer length, which will have a
much increased effective concentration compared to free solution. For instance, hnRNP
A1 has two RRMs separated by a flexible linker; the increase in the avidity of the protein
for RNA is not simply the additive affinity of the two domains, but is increased 1000 fold
by the presence of two binding sites in the same molecule. (Shamoo et al., 1995; Shamoo
et al., 1997). Second, upon first RNA binding, initially disordered regions in the RNA,
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protein, or both can change conformation to facilitate further binding, thereby increasing
the affinity by hundreds to thousands of folds—the induced fit model (Leulliot and
Varani, 2001; Williamson, 2000).
Lastly, homodimerization of tagged I304N fusion protein has been reported to be
defective (Laggerbauer et al., 2001b), but this has only been shown with tagged fusion
proteins. We have not been able to assess homodimerization of I304N FMRP in mouse
brain. Transgenic FMRP in our BAC mice is tagged but with a Flag tag which is too
small to discern from endogenous FMRP, especially in light of the multiple isoforms of
FMRP present. However, the I304N FMRP is in a complex larger than His-tagged
monomer, and we have demonstrated its ability to heterodimerize with FXR1P and
FXR2P showing that I304N FMRP is still capable of protein:protein interactions. In
conclusion, defective KH2 domain mediated RNA binding is likely the primary cause
that leads to the loss of polyribosome association, and hence loss of proper translational
control in I304N mouse brain.

I304N mice have a Fmr1 null-like phenotype
The I304N knock-in mouse phenocopies the disease in most of the phenotypical
analyses we have conducted so far. We have demonstrated their behavioral abnormalities,
e.g. hyperactivity and decreased anxiety, with a battery of assays and their altered
synaptic plasticity such that mGluR induced LTD no longer requires new protein
synthesis. Behavioral and electrophysiologic analysis qualitatively suggest that I304N
knock-in mice are similar to Fmr1 null mice. Comparable macroorchidism to knockout
mice quantitatively shows I304N knock-in mice bear a Fmr1 null like phenotype.
Our behavioral and hippocampal LTD analysis have been performed using adult
male I304N knock-in mice, in which the mutant protein is about 50% of normal levels in
the brain. Attempts have been made using the line of I304N BAC transgenic mice (FVB
background) that has normal levels of the mutant protein in adult brain, but C57BL/6
strain specificity of both behavioral studies and hippocampal LTD findings unfortunately
prevent us from characterizing these BAC mice, which are currently only in the FVB
background.
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Studies have shown that 42% of FMRP expression in peripheral blood smears is
nearly a perfect cut-off for differentiating functional normal males from fragile X males
(Willemsen et al., 1997). All male full mutation patients that express 50% of normal
FMRP protein levels have a non-retarded IQ (>70) (Tassone et al., 1999). Heterozygotes
of many loss-of-function mutations, e.g. the Nova gene, are also much more mildly
affected if at all. Therefore, the phenotypical abnormalities seen in the I304N knock-in
mice are not just due to a 50% decreased protein level, but also the loss of function of the
remaining I304N FMRP, namely RNA binding ability mediated by the KH2 domain.
More phenotypic analyses, for example, classical delayed eye blinking
conditioning (Koekkoek et al., 2005), circadian rhythm (Dockendorff et al., 2002; Inoue
et al., 2002; Morales et al., 2002), dendritic spine morphology (Comery et al., 1997;
Nimchinsky et al., 2001) will be to our interest to further characterize the I304N
mutation.

I304N FMRP does not have a dominant negative effect
Despite the defect of I304N FMRP in association with polyribosomes or binding
to RNAs, the mutant protein does not affect its autosomal paralogs, FXR1P and FXR2P,
as their expression levels, polyribosomal association and mRNP complex sizes are
unchanged. Unlike the I304N patient who has more severe manifestations of Fragile X
Syndrome (DeBoulle et al., 1993), I304N knock-in mice have a Fmr1 null like phenotype
and analogous I307N mutation in Drosophila results in a partial loss of function
phenotype (Banerjee et al., 2007). Biochemical analyses and phenotypical findings in
both mouse and fly suggest that I304N FMRP does not have a dominant negative effect
on FXR1P or FXR2P, but is consistent with a loss of function mutation. Severe Fragile X
symptoms, like IQ below 20 and impressive macroorchidism, observed in the I304N
patient that have not been reproduced elsewhere can be a result of the patient’s genetic
background or an exacerbated effect by the patient’s familial liver disease.

A new and more specific mouse model for the Fragile X Syndrome
Our I304N knock-in mouse models closely after the I304N patient and
phenocopies the disease. It provides a new and more specific mouse model for the Fragile
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X Syndrome. I304N knock-in mouse model has led us to understand that a KH2 mediated
defect in RNA binding is likely the primary cause for polyribosome dissociation and thus
loss of proper translational control, which can in turn contribute to the pathogenesis
underlying the cognitive and behavioral deficits observed in the Fragile X Syndrome.
Therefore identification of the RNA ligands of FMRP in mouse brain would be key to
ultimately understand the pathogenesis of the disease. Once a reliable and comprehensive
set of in vivo RNA targets of FMRP is obtained, the I304N mouse model, in conjunction
with the Fmr1 knockout (Dutch-Belgian Fragile X Consortium, 1994), Fmr1 conditional
knockout (Mientjes et al., 2006), and FMR1 YAC transgenic mice (Peier et al., 2000),
would be a valuable mammalian animal model for the validation of these FMRP RNA
targets and for the study of defined functional roles of FMRP in RNA metabolism in the
process of gene expression. Lastly, trials of clinical treatment can also be tested on the
I304N knock-in mice, since it provides a physiological relevant living system that
phenocopies Fragile X Syndrome.
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Figure 3.1. Generation of Fmr1 BAC transgenic mice. (A) Schematic representation of
the strategy used to insert I304N into Fmr1 BAC via homologous recombination. ~500bp
of sequence on either side of the site of the mutation in exon 10 were cloned into a
targeting vector. (B) I304N recombinant Fmr1 BAC clones were screened with wild type
and mutation specific PCR primers. Clone #130 was selected for pronuclear oocyte
injections to generate transgenic founder mice. (C) Pulsed field gel electrophoresis to
check integrity of BAC I304N Fmr1 DNA (digested by NotI) before pronuclear injection.
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Figure 3.2. Generation of the Fmr1 I304N knock-in mouse model. (A) I304N Fmr1
targeting construct at the KH2 locus of the Fmr1 allele changes an isoleucine to
asparagine in exon 10. An Auto-Cre-NeoR (ACNF) cassette was inserted in a nonconserved region of intron 10. Testis-specific Cre recombinase expression drives autoexcision of the entire ACNF cassette during spermatogenesis in male chimeric mice. (B)
Southern blot analysis of ES cells transfected with the I304N Fmr1 targeting construct.
ES cell clones digested with BamHI were probed with an outer Southern probe
overlapping exon 12. The targeted allele, 2.7kb, can be distinguished from the wild type
locus, 9.6kb.
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Figure 3.3. Light micrographs of sagittal sections of I304N knock-in mouse brains
and testes revealed no microscopic abnormality. Post mortem mouse organs were
fixed in 10% formalin, paraffin embedded, sectioned, stained with hematoxylin & eosin.
(A) (B) wild type cerebellum, (C) (D) I304N cerebellum, (E) (F) wild type cortex, (G)
(H) I304N cortex, (I) (J) wild type hippocampus, (K) (L) I304N hippocampus, (M) (N)
wild type testes, and (O) (P) I304N testes.
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Figure 3.4. Combined weight of both testes of I304N knock-in mice compared with
their wild type or Fmr1 knockout littermates. (A) I304N knock-in mice (42 total)
shows macroorchidism when compared to their wild type littermates (33 total). Testicular
weights were plotted against the age of mice. Data were derived from multiple litters. (B)
For statistical analysis, litters of similar ages were grouped together and data were subject
to student’s t-test. * p<0.03. (C) and (D) The same analysis was applied to I304N knockin mice (32 total) and their Fmr1 knockout littermates (28 total). However, there is no
statistical difference in their testicular weights, up to 600 days of age. (E) Tabulation of
testicular weight analysis of I304N versus wild type or Fmr1 knockout littermates.
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Figure 3.5. Body weight of I304N knock-in mice compared with their wild type or
Fmr1 knockout littermates shows no statistical difference. These are the same male
mice we used to analyze the testicular weight difference.
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Figure 3.6. mRNA analysis of I304N knock-in mouse model. (A) Northern blot of
mouse brain and testicular mRNA shows that I304N Fmr1 mRNA has normal length and
level. Fmr1 mRNA was detected using an in vitro transcribed radiolabeled RNA probe
anti-sense to the 3’UTR of the Fmr1 transcript. β-actin mRNA served as a loading
control. (B) Quantitative RT-PCR confirms that I304N Fmr1 mRNA is expressed at
normal levels. Two sets of primers (left panel primers spanning exon 10 to 11 and right
panel primers spanning exon 2 to 3) were used to amplify the Fmr1 transcript. Data were
quantified by the standard curve method. (C) Sequence alignment of RT-PCR products
from wild type and I304N knock-in mouse brain RNA confirms the presence of the
I304N point mutation. Partial sequence where the I304N mutation is present is shown.
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Figure 3.7. Analysis of mutant protein in adult I304N knock-in mice. (A) Western
analysis and quantification of I304N FMRP in 2 month old mouse brain, testes , and
spleen, probed with FMRP polyclonal antibody, ab17722 (Abcam). Hsp90 served as the
loading control. Signals were quantified by chemiluminescence using Versadoc imaging.
The percentage of I304N FMRP expression compared to wild type in each tissue is
indicated. (B) Western analysis and quantification of I304N FMRP in 6 month old mouse
brain using 2F5 FMRP monoclonal antibody.
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Figure 3.8. Analysis of mutant protein in P14 I304N knock-in mice. (A) Western blot
and quantification of FMRP expression in brain, testes, and spleen of three P14 I304N
knock-in mice versus three wild type littermates. Western blots were probed with FMRP
monoclonal antibody 1C3. (B) Western blot and quantification of I304N FMRP in P14
mouse brain, testes, and spleen, probed with 2F5 FMRP monoclonal antibody,
confirming relatively lower level of the mutant FMRP. (C) Western blot of I304N FMRP
steady state levels in P14 mouse brain with 7G1-1 FMRP monoclonal antibody.
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Figure 3.9. FXR1P and FXR2P have normal expression in I304N mouse brain.
Western blot analysis of FXR1P probed with ML13 and FXR2P probed with 1G2
antibody in P14 I304N vs. wild-type mouse brains.
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Figure 3.10. Expression analysis of I304N BAC transgenic mice. (A) Western blot
(left panel) and quantification (right panel) of I304N expression in adult transgenic mice,
probed with 2F5 antibody. One line of transgenic I304N (TG-I304N-B) has normal
I304N expression in adult brain. (B) At P14, a 4 fold decrease of I304N FMRP protein to
its mRNA ratio was observed in both lines of transgenic I304N mice mimicking the
I304N knock-in, but not in wild type transgenic control mice. Protein level was measured
by Western blot with 2F5 antibody. mRNA level was measure by quantitative RT-PCR
with standard curve method, normalized to GAPDH mRNA.
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Figure 3.11. I304N mRNA has a normal translational profile. I304N and wild type
mouse brain cytoplasmic lysates were centrifuged on a w/w 20-50% linear sucrose
gradient. A260 absorption profiles are shown in (A), 80S monosome and polyribosomes
are indicated. (B) Gradients were fractionated and RNA was collected from each fraction.
Quantitative RT-PCR was performed (ΔΔCt method) for Fmr1 mRNA. Relative Fmr1
mRNA level in each fraction was plotted as a percentage of total Fmr1 mRNA to
illustrate its distribution over the polyribosome gradient. (C) GAPDH was the control
mRNA that did not show distribution changes over I304N vs. wild type polyribosome
gradients.
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Figure 3.12. Mouse brain I304N protein is able to bind G-quartet RNA, but not
kissing complex RNA. Extracts from wild type, I304N knock-in, and Fmr1 knockout
mouse brains were incubated with 96nt radiolabeled RNA generated by in vitro
transcription encoding (A) G-quartet RNA and (B) kissing complex RNA. Samples were
UV crosslinked, RNase treated, immunoprecipitated with FMRP specific 7G1-1
antibody, run on SDS-PAGE gels, transferred to nitrocellulose and exposed to
phosphoimager to detect radiolabeled RNA. The arrow indicates immunoprecipitated
FMRP-radiolabeled G-quartet RNA complex in (A) and FMRP-kissing complex RNA in
(B). (C) 7G1-1 immunoprecipitated wild type and I304N FMRP were detected using
anti-FMRP 2F5 antibody.
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Figure 3.13. Co-immunoprecipitation of I304N with its autosomal paralogs, FXR1P
and FXR2P. FMRP was immunoprecipitated using the 7G1-1 antibody. FXR1P and
FXR2P were detected using antibody ML13 (gift from Dr. Eduoard Khandjian) and 1G2,
respectively. Wild type and Fmr1 knockout mice were used as positive and negative
controls.
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Figure 3.14. The majority of I304N FMRP is dissociated from polyribosomes while
FXRPs are still on polyribosomes in I304N knock-in mouse brain. (A) Mouse brain
cytoplasmic extracts were centrifuged on a w/w 20-50% linear sucrose gradient.
Fractions were collected; positions of the 80S monosome and polyribosomes are
indicated on the A260 profile. FMRP (7G1-1 antibody), FXR1P, and FXR2P migration
were analyzed by Western blot. Ribosomal protein S6 distribution further confirms the
polyribosome sedimentation profile. (B) Quantification of chemiluminescence by
Versadoc imaging of the Western blot of I304N knock-in vs. wild type FMRP in (A), the
percentage of FMRP present in each fraction as a function of the total FMRP signal in the
gradient is indicated.
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Figure 3.15. Most of the I304N FMRP in I304N BAC transgenic mice does not
cosediment with polyribosomes. Proteins from 400 ul of each sucrose gradient fraction
were TCA precipitated and resolved by SDS-PAGE. FMRP was detected by Western blot
using 7G1-1 antibody.
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Figure 3.16. The majority of I304N FMRP is in an abnormally small RNaseresistant complex. Top panels show the absorption profiles at 280nm of Superose 6 gel
filtration of wild type and I304N mouse brain lysates, without and with RNase treatment.
The molecular sizes in kDa depicted on top of the profile were calibrated using molecular
weight markers. Bottom panels are Western blots of wild type or I304N FMRP, FXR1P,
FXR2P corresponding to the fractions of the absorption profiles. The RNA binding
protein Nova and hsp90 are controls. (A) The wild type FMRP-mRNP eluted in the void
volume of the column corresponding to a relative size > 40,000 kDa. (B) I304N is in a
much smaller complex of 100-300 kDa. After complete RNase A and T1 digest, the large
wild type FMRP complex falls apart to the size of the native I304N FMRP complex (C)
and the I304N complex does not shift in its relative size (D).
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Figure 3.17. The I304N FMRP core particle is in a complex larger than the I304N
monomer. Full length His tagged I304N FMRP was denatured by heating at 95oC for
10min and spiked into mouse brain lysate. Lysate was then run on a Superose 6 column;
fractions were collected and subject to Western blot analysis. Denatured I304N FMRP
was detected using HRP conjugated anti-His antibody.
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Figure 3.18. Behavioral assays comparing I304N knock-in mice and their wild type
littermates. Activity in open field test: (A) total distance traveled, (B) vertical distance
(rearing). Anxiety related responses: (C) center:total distance ratio in an open field, (D)
light to dark transition, (E) time spent in the dark chamber. Startle habituation: (F)
acoustic startle response in PPI test, (G) %PPI with increasing prepulse level.
Conditioned fear: (H) fear response in context test, (I) fear response in acoustic
conditioned stimulus test. (J) Hotplate test for sensitivity to pain. (K) Marble burying for
obsessive-compulsive behavior. (L) Audiogenic seizure. (M) Tabulation of behavioral
test summary and comparison with historical findings on Fmr1 knockout mice.
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Figure 3.19.

Figure 3.19. Protein synthesis-independent mGluR-LTD in I304N knock-in mice.
Evoked extracellular field potentials (FPs) from CA1 of acute slices from 30-90 day old
wild type and I304N knock-in littermates are plotted as a percent of baseline (pre-DHPG
or PP-LFS). (A) (B) Anisomycin inhibits DHPG-induced LTD in wild type littermates,
but has no effect in I304N knock-in mice (*; p=0.02). (C) (D) Anisomycin inhibits
synaptically induced LTD (with PP-LFS; *; p=0.004) in wild type mice, but not I304N
knock-in mice. The magnitude of LTD between wild type and I304N knock-in mice is
not different under control conditions, but is enhanced in the presence of anisomycin
(ANOVA and subsequent Fisher PLSD; p<0.05).
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CHAPTER IV. IDENTIFICATION AND VALIDATION OF
FMRP IN VIVO RNA TARGETS
Introduction
FMRP has been well-characterized as an RNA binding protein; both in vitrotranslated and purified FMRP bind RNA ribohomopolymers and ~4% of fetal brain
mRNAs in vitro, (Ashley et al., 1993b; Brown et al., 1998; Siomi et al., 1993b). Like the
majority of RBPs, FMRP harbors multiple RNA binding motifs, two tandem KH
(hnRNPK homology)-type RNA domains (Siomi et al., 1994; Siomi et al., 1993b), a
spacer and an arginine- and glycine-rich RNA binding domain (RGG box) (Siomi et al.,
1993b). The N-terminus may also have RNA binding ability as assessed by a
ribohomopolymer assay (Adinolfi et al., 1999) and recent data suggesting that the Nterminus binds BC1, a neuron-specific noncoding RNA (Zalfa et al., 2005). In both cell
lines and brain lysates subjected to sedimentation in sucrose gradients, FMRP has been
found to associate with translating polyribosomes as part of a large messenger
ribonucleoprotein (mRNP) complex, and this has been shown to be an RNA-dependent
interaction (Corbin et al., 1997; Eberhart et al., 1996; Feng et al., 1997a; Feng et al.,
1997b; Khandjian et al., 1996; Khandjian et al., 2004; Stefani et al., 2004). Since the
study of the I304N mouse model suggests that a key function of FMRP in mediating
normal cognition is sequence-specific RNA binding, the interest in identifying RNA
ligands for FMRP is heightened. Identification of the RNA targets that FMRP binds to in
vivo would be a key step in ultimately understanding the normal function of the protein
and the mechanistic defects caused by the protein’s absence.
However, identification of FMRP targets has not been easy and many labs have
attempted with various approaches. Our lab has used in vitro RNA selection assays
(SELEX) and identified G quartet and kissing complex RNA motifs as RNA ligands of
the FMRP RGG box and KH2 domain respectively (Darnell et al., 2005a; Darnell et al.,
2001). The G quartet motif has been independently identified by the candidate gene
approach in the 3’ end of Fmr1 coding sequence that FMRP specifically binds (Schaeffer
et al., 2001). Co-immunoprecipitation (IP) of FMRP-mRNP complexes and extraction of
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RNA for microarray analysis has identified a repertoire of neuronal RNAs (Brown et al.,
2001), some of which also contained G quartet elements. Among these candidates,
Mtap1b (MAP1B) has been validated as a target RNA in vivo, using a Drosophila model
of the fragile X syndrome. Aberrations in the architecture of neuronal synapses were
noted in flies in which the dFxr gene (the Drosophila homologue of FMR-1) had been
disrupted. Double deletion of dfxr and futsch, the homologue of Mtap1b, restored normal
synaptic architecture, supporting the hypothesis that FMRP negatively regulates
translation of Mtap1b mRNA (Zhang et al., 2001b). Despite the fact that these targets are
widely studied, there are still some uncertainties. Fusion proteins lack post-translational
modification and both phosphorylation and methylation status of RGG box has shown to
affect FMRP RNA binding (Ceman et al., 2003a; Denman, 2002; Stetler et al., 2006).
Problems with co-IP of mRNPs include precipitation (which must be done under low to
moderate stringency to avoid loss of associated RNAs) of additional associated RBPs
along with their targets, creating signal to noise problems, and reassociation of RBPs
with aberrant RNAs after cell lysis (Mili and Steitz, 2004). Other different techniques,
including antibody-positioned RNA amplification (APRA) (Miyashiro et al., 2003), yeast
3-hybrid (Dolzhanskaya et al., 2003; Sung et al., 2003), and cDNA SELEX (Chen et al.,
2003) have identified distinct sets of mRNAs associated with FMRP-mRNP complexes
adding to the repertoire of FMRP’s potential RNA targets. Moreover, a few more targets
have been identified by candidate gene approach (Todd et al., 2003; Xu et al., 2004; Zalfa
et al., 2003). The long lists of RNAs with limited overlap from different laboratories
make it difficult to distinguish true FMRP targets from falsely identified ones and would
necessitate an enormous amount of work of rigorous validation.
To overcome this, our laboratory has developed in vivo UV crosslinking and
immunoprecipitation (CLIP) analysis (Fig. 4.1) (Ule et al., 2005a; Ule et al., 2003). It has
been used successfully to identify the genome-wide binding sites for Nova family
members on pre-mRNAs. The sequence of the CLIP tags (short RNA sequences directly
crosslinked to Nova and cloned using this technique) has confirmed the specific binding
site for Nova previously identified by in vitro RNA selection to be YCAY clusters. In
addition, the location of the tags on a specific set of pre-mRNAs, combined with the
results of in vivo splicing assays in mouse models, has provided a predictive “map” that
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correctly predicts the splicing outcome of Nova-dependent targets. (Ule et al., 2003; Ule
et al., 2006).
CLIP analysis offers a few advantages over previously used techniques in
identifying bona fide in vivo RNA targets (Ule et al., 2005a; Ule et al., 2003). First, it
uses UV to crosslink protein and RNA that directly interact with one another on the order
of 1 angstrom apart in intact brain tissues. Second, the UV photocrosslinking step in the
CLIP protocol forms irreversible covalent bonds between RNA and proteins, allowing for
unusually rigorous purification of RNA-protein complexes in multiple steps, like
stringent IP, boiling complexes in SDS-sample buffer, running complexes on SDS-PAGE
gels and transferring to nitrocellulose, through which non-specific free RNA can be
removed, lowering the false-positive rate. Third, limited RNase digestion allows for the
isolation of the sequence involved in protein binding, providing a snapshot of where an
RBP is bound in vivo, which conventional IP techniques cannot provide. Therefore, we
set out to use CLIP to identify FMRP RNA targets.

Results
Adaptation of CLIP for FMRP to identify RNA targets
The first step of adapting CLIP for FMRP was to work out the IP condition for
FMRP. Several changes in the protocol optimized for the Nova experiments had to be
altered. First, we had to lower the ultracentrifugation step from 60,000rpm to 30,000rpm
(TLA 120.2 rotor), an experimental step to separate large ribosomal particles from
protein-RNA complexes before the IP. At 60,000rpm, half of the FMRP was lost in the
pellet. After a 30,000rpm spin however, the vast majority of FMRP was retained in the
supernatant (Figure 4.2A). Second, it was necessary to screen for a good FMRP-specific
antibody that could IP under stringent conditions. Out of 7G1-1, 2F5, 6B5 and 7B8, only
7G1-1 was able to IP FMRP in 1XPXL buffer which contains 0.5% NP-40, 0.5% Na
deoxycholate as well as 0.1% SDS (Figure 4.2B). Furthermore, 7G1-1 antibody showed
no cross-reactivity with, (Brown et al., 2001) and did not co-IP, FXR1P or FXR2P in
the1XPXL buffer (Figure 4.3B). We further optimized IP efficiency by testing a number
of parameters: dynal beads vs. sepharose beads, protein A vs. protein A and G mix, with
or without rabbit anti-mouse Fcγ bridging antibody, monoclonal supernatant vs. mouse
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ascites, and the amount of 7G1-1 antibody optimal for each IP. 7G1-1 antibody of IgG
isotype 2b has a moderately strong affinity for protein A. Rabbit bridging antibody
strengthened binding to protein A beads and doubled the bead capacity. We found that
400ul dynal A beads with 120ug rabbit anti-mouse Fcγ antibody and 8ul of 7G1-1 mouse
ascites at 5mg/ml gave the optimal FMRP IP (Figure 4.2C) where the majority of FMRP
was depleted (Figure 4.3B and 4.4B).
We used postnatal day 8 mouse brains for FMRP CLIP since dendritic spine
abnormalities in Fmr1 knockout mice have been reported to be the most severe at one
week of age and subside by postnatal two to three weeks (Nimchinsky et al., 2001). Noncrosslinked wild type mouse brain and crosslinked Fmr1 knockout brain were processed
in parallel as negative controls. Non-crosslinked wild type mouse brain lysate didn’t have
any radiolabeled RNA signal (Figure 4.3A). Free RNAs, if not covalently crosslinked to
a protein, were “filtered” out through various purification steps of the CLIP procedure. In
wild type crosslinked samples, RNA signal in complex with FMRP was observed
concentrated at molecular sizes greater than the Mr of FMRP (Figure 4.3A). In
comparison, the Fmr1 knockout sample had a much reduced RNA signal (Figure 4.3A).
We excised the region of FMRP-RNA complex from the protein gel and from
comparable regions in Fmr1 knockout and non-crosslinked wild type sample (Figure
4.3A), digested the protein, added the 5’linker, RT-PCR amplified the RNA, and
separated the PCR products on a denaturing polyacrylamide gel. We obtained a strong
nucleic acid (NA) smear from wild type sample, very little signal from Fmr1 knockout,
and none from non-crosslinked sample (Figure 4.3C).
CLIP experiments on Nova have demonstrated that RNA:protein complexes run
quite true to size on SDS-PAGE gels. For example, RNA-protein complexes that contain
RNAs of ~50-70 nts run ~15-20 kDa larger than the Mr of the protein alone (Ule et al.,
2005a). We next explored whether the size of RNAs we obtained corresponded to the
predicted migration of RNA-FMRP complexes on the protein gel. We excised a few thin
bands corresponding molecular weights of 85, 90, 95, and 115 kDa from both wild type
and Fmr1 knockout samples (Figure 4.4A). As in the previous experiment, after RT-PCR
amplification, NA signals were present in wild type and very little in FMR-1 knockout
sample (Figure 4.4C). As the size of RNA-protein complexes increased from 90 to 95
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kDa, NA smears also increased in size (Figure 4.4C). 95 kDa RNA-FMRP complexes
would have predicted RNA size of 60 nts (95 kDa minus 75 kDa for FMRP leaves 20,000
Da, which correspond to ~60 nts). Indeed we recovered RNAs of an average of 64 nts
(average of 44 nts CLIP tag plus 20 nts of 3’ linker). The size of the RT-PCR product
contained both linkers. So the PCR products appeared to be about 80mers. Our data
suggest RNAs extracted from 95 kDa as well as 90 kDa are RNAs directly crosslinked to
FMRP. To our surprise, the 115 kDa FMRP:RNA band generated sharp NA bands
instead of the smears present in both wild type and Fmr1 knockout samples. The size of
these NAs was unexpectedly small. They appear to be approximately 55-60 nts in length
on the gel, corresponding to original RNA tags of 19-24 nts plus linkers totally 36 nts.
We pursued this observation and found that commercially available 7G1-1 antibody we
used for FMRP CLIP was contaminated by a pan-Argonaute antibody (described in detail
in Chapter 5). The sharp NA bands present in both wild type and Fmr1 knockout were in
fact microRNAs. Here microRNA CLIP, serving as an elegant control for FMRP CLIP,
further confirmed that the NA signal amplified from wild type but not knockout mice,
derives from RNAs specifically bound by FMRP, not other RBPs. Otherwise, like
microRNAs, RNAs would be amplified from both wild type and Fmr1 knockout samples.
FMRP CLIP was repeated with three biological replicates, all at postnatal day 8.
A total of 1698 unique wild type FMRP RNA tags were collected from these three
experiments. In order to clone from the faint RNA signal from Fmr1 knockout, we had to
amplify 5 more RT-PCR cycles than for wild type. We collected 1106 unique Fmr1
knockout RNA tags, which served as a control for background noise of our CLIP
experiment. We used a subtractive method (WT minus KO) to obtain a list of FMRP
CLIP targets.

FMRP CLIP tags distribute evenly on mature mRNAs
Out of 1698 wild type CLIP tags, 1013 were in known genes and of these, 66%
were exonic hits (Figure 4.5). In contrast, only 27% of 1106 Fmr1 knockout RNA tags
were exonic (164 out of 613 tags in known genes). In comparison, we have previously
done CLIP on the nuclear splicing factors, Nova and bPTB, which had 24% and 8% of
exonic hits respectively.
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Out of the FMRP exonic hits, 30 (5%) tags were located in 5’UTRs, 510 (76%)
tags in coding sequence, and 128 (19%) in 3’UTRs. The number of FMRP exonic hits
was plotted with respect to their positions on mRNAs, which was best fitted for linear
regression with r2=0.99 (Figure 4.6A), indicating FMRP likely binds evenly along the
length of mRNA.
Our top FMRP candidate gene based on number of sequenced tags is
adenomatosis polyposis coli (APC) had 31 hits, which were also distributed all over the
APC mRNA (Figure 4.6B), consistent with our analysis of all FMRP CLIP tags.

CLIP identifies Mtap1b and a few previously identified targets
The UCSC mouse genome browser, mm8 (updated in Feb 2006), was used to
annotate all of our CLIP tags. Combining P8 biological replicates for a total 1698 FMRP
tags, we generated a list of FMRP candidate genes, having ≥2 RNA tags in the wild type
sample (Table 4.I), while under-represented in the Fmr1 knockout sample. This list of
FMRP targets was quite reproducible between biological replicates; many of them were
identified from more than one CLIP experiment. The adenomatosis polyposis coli (APC)
mRNA was our top target as it had a total of 31 hits and was identified in all three CLIP
experiments. The previously identified and validated target Mtap1b (Brown et al., 2001;
Darnell et al., 2001; Zhang et al., 2001b) was one of our top candidates. In addition,
genes like Spnb3 (5 hits by our FMRP CLIP), Rab6ip1 (3 hits), Aatk (2 hits), Lphn1 (1
hit), Bai2 (1 hit), Munc13a (1 hit), Cacna1d (1 hit) and Psd95 (1 hit) on our list
overlapped with previous findings (Brown et al., 2001; Chen et al., 2003; Todd et al.,
2003). Abundant non-specific sequences, like ribosomal RNA, were seldom hit and did
not out-compete the low abundance of true target mRNA sequences.

Total brain CLIP targets overlap well with polyribosome CLIP
One concern with the FMRP CLIP experiment from total mouse brain was the
low but present background signal in Fmr1 knockout sample. Our lab has worked out a
new and improved approach to solve the background issue by using polyribosome
associated FMRP for the CLIP experiment (Darnell, JC personal communication). This
method not only removes the nuclei, where many RNA binding proteins are present, but
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also takes advantage of sucrose gradient fractionation as an additional step of purification
of FMRP:RNA complexes. Furthermore, high throughput sequencing was used to obtain
hundreds of thousands of FMRP CLIP tags. Polyribosome FMRP CLIP was performed at
multiple developmental ages, using a FMRP-specific polyclonal antibody in addition to
the 7G1-1 antibody.
FMRP CLIP targets obtained from total mouse brain at P8 matched extremely
well with targets of polyribosome CLIP using both antibodies (Table 4.I). Many of the
top listed FMRP targets from total brain CLIP also had a considerable number of hits
from polyribosome CLIP (Table 4.I). 21 of top 30 polyribosome targets were present in
the total brain CLIP. Fourteen of the top 30 polyribosome targets, Bsn, Adcy1, Kif1a,
Kif1b, Mtap1b, Atp2b2, Apc, Ptprs, Kif5a, Fasn, BC067047, Huwe1, Itpr1, and Grin2b
were hit ≥2 times in the total brain CLIP. Therefore, we have obtained a reliable set of
FMRP targets.

Function categories of FMRP targets
We used GOminer (Gene Ontology) to categorize encoded functions of our top
FMRP targets (hits≥2) (Table 4.II and Figure 4.7), an unbiased assessment of strict
statistical analysis. Age matched mouse brain total RNA was used as the control set (data
from D. Licatalosi, Darnell lab). We found FMRP targets were highly enriched in
function categories of cytoskeleton organization, microtubule based processes, synaptic
transmission, neurotransmitter secretion, and cell-cell signaling (p< 0.001 and false
discovery rate < 0.03).
GOminer analysis was further supported by more detailed individual annotation
by Pubmed search confirming FMRP targets encode for proteins enriched in coherent
functions related to cytoskeleton organization, cytoskeleton-based intracellular movement
and microtubule-based movement, and the neuronal synapse (Table 4.III). The category
of cytoskeletal organization and movements included FMRP target genes Mtap1b, Kif1a,
Kif1b, Kif5a, Kif5c, Dnchc1, Dncic1, Myo5a, Dst, Macf1, Plec1, Spnb2, Spnb3, and
Hdh. Interestingly, these genes also belonged to closely related superfamilies, e.g. the
kinesin family (microtubule plus end motors), the dynein family (microtubule minus end
motors), and myosin (actin based motors). The category of synaptic functions included
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Gabbr1 (2 hits), Grin2a (2 hits), Grin2b (2 hits), Psd95 (1 hit), Akap6 (4 hits), Dap-3 (1
hit), Pak1 (1 hit), Pak6 (1 hit), Camk2a (1 hit), Arhgap5 (2 hits), Nlgn2 (2 hits), Nlgn 3 (1
hit), Itsn (2 hits) found at the postsynaptic side of the synapse, and Bsn (3 hits), Pclo (5
hits), Munc13a (1 hit), Syn1 (1 hit), Syn3 (2 hits), Caskin1 (3 hits), Cacna1e (2 hits),
Cacna1d (1 hit), Stxbp1 (1 hit), Nrxn1 (1 hit), VAMP2 (1 hit) which are presynaptically
localized (Table 4.III). Some of these targets closely interact with one another forming a
network (Figure 4.8). Although FMRP is widely thought to play a role in postsynaptic
local translation effecting changes in synaptic strength in response to synaptic input , our
data suggest FMRP may also have a role in regulating presynaptic functions.

Validation of FMRP CLIP targets
Knowing the set of RNAs that FMRP binds to in vivo, we are interested in asking
what regulatory roles FMRP has on these targets. The precise physiological function of
FMRP has not been defined. The most likely function of FMRP, given the sum of the
current literature in the field is in translational regulation perhaps coupled with delivery
of mRNAs to neuronal processes and possibly regulated export from the nucleus. A
strong piece of evidence is that FMRP is associated with polyribosomes in cell culture
and mouse brain, in an RNA dependent manner (Corbin et al., 1997; Feng et al., 1997a;
Feng et al., 1997b; Khandjian et al., 1996; Khandjian et al., 2004; Stefani et al., 2004).
FMRP has been shown to be a translational inhibitor in rabbit reticulocyte lysate and
when over-expressed in cell culture, but these studies used candidate mRNAs which have
little overlap with identified FMRP targets (Laggerbauer et al., 2001b; Li et al., 2001;
Mazroui et al., 2002; Zhang et al., 2001b). Both systems are also considerably different
from endogenous cellular environment. Overexpressed FMRP appears to nonspecifically
repress translation. The best in vivo evidence for a role in translational control in neurons
comes from combined biochemical data and Drosophila genetics. Mutations of
futsch/mtap1b or dfxr alone lead to aberrations in architecture of neuronal synapses, but
double mutation restores synaptic architecture (Zhang et al., 2001b). Together with the
finding that Mtap1b mRNA is co-IPed with FMRP and has increased association with
polyribosomes (Brown et al., 2001), these data support a role for FMRP as a translational
repressor of mtap1b mRNA.
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-Western analysis of target protein levels
In order to asses whether the lack of FMRP could lead to changes in steady state
protein levels of FMRP targets, we used Western blots to examine protein levels encoded
by FMRP top targets in wild type vs. Fmr1 knockout mouse whole brain at P8, the same
developmental age as we performed CLIP experiment. No significant difference was
observed. We then repeated the Western analysis at different developmental ages: P8,
P14, and P40, and in finer brain regions: cortex, cerebellum, hippocampus, diencephalon,
and brain stem. Protein levels of APC, Kif1a, Kif5a, Akap6, Grin2b, Munc13 (data not
shown) as well as an APC downstream effector, phosphorylated beta-catenin, were
examined. But no significant difference in protein levels were found in wild type vs.
Fmr1 knockout littermates (Figure 4.9). Kif5a is shown as one example; data are not
shown for the rest of the targets.
-Quantitative RT-PCR examination of target mRNA translational profiles
In many cases, FMRP target mRNAs encode for very large proteins; e.g., APC is
313kDa, Kif1a 186kDa, Kif1b 195kDa, Mtap1b 271kDa, Macf1 488kDa, Bsn 434kDa,
Pclo 550kDa, Akap6 255kDa, and Dst 592kDa. Aside from Western blot’s heavy
dependence on good antibodies, there is technical difficulty with electrophoresis and
transfer of very large proteins. One alternative is to analyze the translational profile of
FMRP targets by examining their mRNA distribution on polyribosome gradients. In
many instances mRNAs will be present on polyribosomes when they are being actively
translated but shift to monosome/ mRNP fractions if their translation is inhibited at the
initiation stage.
Microarray screens of polyribosome-associated mRNAs have previously
generated contrasting results. Using transformed human lymphoblastoid cells, 251
mRNAs have shown altered polyribosome distribution in fragile X patients vs. normal
controls (Brown et al., 2001). On the other hand, polyribosome associated mRNAs from
wild type and Fmr1 knockout mouse cerebral cortex show a remarkable lack of
difference (Fraser, CE , PhD thesis). One possibility for these contradictory findings is
that FMRP control of translational status of target mRNA is very subtle, such that
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pooling polyribosome fractions masks the shift of mRNAs that shift only by one or more
fractions rather than from polysomes to the mRNP fractions.
We optimized quantitative RT-PCR to examine mRNA levels in every fraction of
the polyribosome gradient and tested the distribution of several FMRP mRNA targets.
GAPDH was used as control mRNA that did not show distribution changes between wild
type and Fmr1 knockout polyribosome gradients (Figure 4.10A). Our data were
consistent with mouse brain polyribosome microarrays in that FMRP target mRNAs
showed remarkably similar distribution on polyribosome gradients in wild type vs. FMRP
null littermate mouse brains (Figure 4.10B, C, D, E and F), including Mtap1b mRNA
(Figure 4.10C).
In Chapter 3 we described the generation and characterization of a novel mouse
model for Fragile X Syndrome, the introduction of the I304N KH2 domain mutation by
homologous recombination. One of the goals of generating this mouse was to use it as
another disease model in which to look at the metabolism of putative FMRP target
mRNAs. Therefore we looked at the distribution of mtap1b mRNA in polyribosome
gradients derived from the I304N mice compared with wild-type littermates. In this
system, as in the Fmr1-null mice, Mtap1b mRNA was unchanged in its distribution on
polyribosomes (Figure 4.11).
-Use of Fmr1 and FXR2 double knockout mice
Fmr1 and its autosomal paralogs, FXR1 and FXR2 share the same conserved gene
structure suggesting that they are derived from a common ancestral gene (Kirkpatrick et
al., 2001). It is possible that the effect of loss of FMRP on its target mRNAs is
compensated by the functional redundancy of FXR1P and FXR2P (Spencer et al., 2006).
FXR1 and FXR2 knockout mouse models have both been successfully generated
(Bontekoe et al., 2002; Mientjes et al., 2004). Because FXR1 knockout mice, which have
a striated muscle defect, die shortly after birth due to cardiac or respiratory failure
(Mientjes et al., 2004), we were not able to obtain a triple knockout of all three genes. We
analyzed wild type vs. Fmr1/FXR2 double knockout mice (Dr. David Nelson provided
the FXR2 knockout mice), which have been reported to have an exaggerated behavioral
phenotype (Spencer et al., 2006). Western blot analysis was used to detect protein level
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changes of APC, Akap6, Kif1a, Kif5a, Grin2b, and Munc13 in cortex, cerebellum and
hippocampus at postnatal age of 10 days, but no significant differences were observed in
double knockouts (n=5) vs. wild type mice (n=7). A few examples, Kif1a, Kif5a, and
Grin2b protein levels in P10 hippocampus are shown (Figure 4.12).
-Preliminary analysis of localized translation in synaptoneurosomes
FMRP has also been proposed to have a role in the transport of translationally
dormant mRNA from cytoplasm to synapse and in the regulation of localized translation
(Antar et al., 2004; Antar et al., 2005; De Diego Otero et al., 2002; Greenough et al.,
2001; Muddashetty et al., 2007). We examined the steady state protein levels of the
synaptically localized FMRP targets Akap6, Grin2b, Munc13, and Camk2a, in
synaptoneurosome preparations from mouse brain (Shin et al., 2004), however no
differences were found in wild type vs. Fmr1 knockout or Fmr1/FXR2 double knockout
mice. A few examples of tested targets are shown (Figure 4.13).

Discussion
Since the study of I304N mouse model suggests that a key function of FMRP in
mediating normal cognition is sequence-specific RNA binding, the interest in identifying
RNA ligands for FMRP is heightened. Despite the fact that many labs have attempted
this with various approaches we still lack a reproducible and reliable set of FMRP targets
due to intrinsic problems associated with each of these methods.

CLIP, a newly

developed methodology in our lab has several advantages over previous methods for
identifying the in vivo RNA ligands of RBPs. These include crosslinking of RBPs to
RNA ligands before cell lysis, and the stringent purification of specific RBPs possible
because of the covalent association of RBP to RNA. Optimizing this method for FMRP,
we obtained a set of FMRP RNA targets from mouse brain, including Mtap1b. Top
targets of the set were reproducible between biological replicates and overlapped well
with targets identified by FMRP polysome CLIP, a new and improved approach.
Therefore, we have obtained a reliable set of RNA targets bound by FMRP. These RNA
targets had coherent biological functions related to cytoskeleton organization and
neuronal synapses, which fit well with fragile X biology. Knowing what set of RNAs
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FMRP binds to in vivo, we were interested in asking what regulatory roles FMRP has on
these targets. However, we encountered a hurdle. Despite our various attempts, we have
not been able to detect changes in RNA metabolism of these targets. Since the precise
functions of FMRP have not been defined, continuing efforts will focus on developing
functional assays to eventually validate these targets in animal models.

CLIP tag locations likely indicate FMRP regulates elongation
CLIP not only identifies RNA targets, but the RNA binding sites bound by RBPs.
It captures a snapshot of RNA sequences RBPs bind at the time of UV crosslinking.
FMRP CLIP tags are distributed over the length of target mRNAs, indicating that FMRP
likely binds all over mature mRNAs, without preference for UTRs or coding sequences.
FMRP has been previously reported to be a translational inhibitor of its target RNAs
(Laggerbauer et al., 2001b; Li et al., 2001; Mazroui et al., 2002; Zhang et al., 2001b) and
it has been shown to associate with polyribosomes (Corbin et al., 1997; Feng et al.,
1997a; Feng et al., 1997b; Khandjian et al., 1996; Khandjian et al., 2004; Stefani et al.,
2004). Therefore, it is not likely that FMRP inhibits translation initiation, or else it would
have been found in monomeric 80S ribosome fractions. Also, one would expect most of
the CLIP tags to be found in the 5’UTR or near the initiator methionine if FMRP blocked
initiation of translation. Indeed, even after puromycin treatment, FMRP cosedimented
with the largest remaining polyribosomes containing three to four ribosomes rather than
with the much more prominent peak of monomeric ribosomes (Stefani et al., 2004).
These findings together with our data suggest that FMRP is more likely to modulate
translation at the step of elongation, instead of at the initiation step.
Although FMRP CLIP tags were found to lie all over the length of target mRNAs,
this finding does not rule out pockets of high affinity binding sites on mRNAs FMRP
prefers. The number of tags we sequenced, even for APC, does not give a high enough
sample size for us to discern these high affinity sites. High throughput sequencing is
needed. FMRP has been shown to prefer binding to purines over pyrimidines; G-quartet
and kissing complex RNAs have been identified as high affinity RNA motifs for FMRP
RNA binding domains (Brown et al., 2001; Darnell et al., 2005a; Darnell et al., 2001;
Schaeffer et al., 2001). Analysis of high throughput CLIP tag densities on mRNAs can
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help to discern FMRP preferred binding sites in vivo, which can ultimately resemble
identified in vitro motifs, as has been shown for the Nova family of RBPs (Ule et al.,
2003; Ule et al., 2006; Ule et al., 2005b).

FMRP

mRNA

targets

encode

coherent

functions--cytoskeletal

organization and synaptic transmission
-Understanding APC
APC is our top target with a total of 31 hits. APC is best known as a tumor
suppressor. APC forms a complex with AXIN/GSK-3β that phosphorylates β-catenin and
leads to its degradation. Deletion of APC allows accumulation of β-catenin/Tcf-4 and
activation of downstream growth promoting genes that lead to the development of
inherited and sporadic forms of colorectal cancer. APC is also highly expressed in the
brain (Brakeman et al., 1999). APC is especially enriched in the tips of neurites (Shi et
al., 2004; Votin et al., 2005) and is required for Par3 localization to the axon tip, where
Par3/Par6 are required for neuronal polarity (Shi et al., 2004). APC binds microtubules
directly and indirectly through EB1, a microtubule plus-end-binding protein (Barth et al.,
2002; Su et al., 1995). APC promotes microtubule assembly and bundling in vitro
(Munemitsu et al., 1994; Zumbrunn et al., 2001) and its association with microtubules in
the growth cone is important during axon outgrowth induced by nerve growth factor
(NFG) (Zhou et al., 2004). Although initially surprising to us, APC indeed can be a
potential target of FMRP. Its role in microtubule assembly and neurite outgrowth fit
extremely well with the abnormal neurite morphology seen in fragile X patients as well
as mouse and fly models of the disease.
-FMRP targets in the functional category of cytoskeletal organization
FMRP mRNA targets encode proteins with coherent biological functions. They
are especially enriched in the categories of cytoskeletal organization and synaptic
transmission. In the category of cytoskeleton organization, FMRP targets consist of giant
cytoskeletal proteins that crosslink cytoskeletal filaments--spectraplakin family members,
e.g. Dst, Macf1, and Plec1, which are able to interact with all three cytoskeletal elements:
actins, microtubules, and intermediate filaments or proteins that crosslink cytoskeleton to
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membrane receptors--spectrin family, e.g. Spnb2, Spnb3 (Roper et al., 2002). Mutation of
shot, the only spectraplakin gene in Drosophila, causes defects in axon fasciculation and
guidance and dendritic branching in embryonic CNS and PNS (Roper et al., 2002).
FMRP targets also include cytoskeletal motor proteins, which are microtubule
plus end directed kinesins, e.g., Kif1a, Kif1b, Kif5a, Kif5c, microtubule minus end
directed dyneins, e.g., Dnchc1, Dncic1, and actin based motors, e.g., Myo5a. These
motor proteins transport organelles, proteins, or mRNA and tightly control subcellular
localization of their cargoes, especially in highly polarized cells, like neurons (Guzik and
Goldstein, 2004). Kif1a and Kif1b transport synaptic vesicle precursors containing
synaptic vesicle proteins such as synaptotagmin, synaptophysin, Rabphilin3A; Kif5
transport vesicles that contain APPs (amyloid precursor proteins) and vesicles containing
APOERs (apoliprotein E receptor 2) to the presynaptic terminals. Kif5 also participates in
slow axonal transport of cytoskeletal proteins. In dendrites, AMPA glutamate receptors
are transported by the motor Kif5, mediated by adaptor/scaffolding protein, glutamate
receptor interacting protein 1 (Grip1) (Hirokawa, 2006; Hirokawa and Takemura, 2005).
One proposed function of FMRP has been targeting of translationally dormant mRNAs
from cytoplasm to synapses, where they await signaling that would allow local
translation (Antar et al., 2005; De Diego Otero et al., 2002; Ferrari et al., 2007;
Muddashetty et al., 2007), We speculate that FMRP may affect subcellular localization
not only through a direct effect on mRNAs bound by FMRP, but also an indirect effect
through its regulation on these cytoskeletal motor proteins.
-FMRP targets form a close network at neuronal synapse
Aside from cytoskeletal organization, FMRP mRNA targets encode proteins
present at the neuronal synapse. Receptors in both excitatory and inhibitory synapses,
Grin2a, Grin2b and Gabbr1 have been identified as FMRP targets. At the excitatory
synapse, Grin (the NMDA receptor) is associated with post-synaptic MAGUK, e.g.
PSD95, also a CLIP target, which anchored to the membrane via palmitoylation.
Additionally, PSD95 interacts with a number of multi-domain scaffold proteins, e.g. Akinase anchored

proteins (AKAP)

and

guanylate kinase associated

proteins

(SAPAP/GKAPs)—Akap6 and Dap-3 that belong to these two families respectively have
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been CLIPed as FMRP targets as well. This is one of many examples that FMRP can
bind and regulate mRNAs encoding proteins that interact with one another in a functional
pathway.

AKAP

recruits

cAMP-dependent

protein

kinase

A

(PKA)

and

calcineurin/protein phosphatase 2B (CN/PP2B) which regulate many phosphorylationdependent events that influence synaptic plasticity, e.g. actin regulation, membrane
receptor anchorage or endocytosis, and etc. On the other hand, SAPAP/GKAPs recruits
shank proteins, which possess numerous protein-protein interaction domains, thus linking
the post-synaptic scaffold with a variety of signaling molecules. One of the protein
families that shank recruits to the excitatory synapse is p21-activated kinase (PAK) and,
interestingly, we CLIPed Pak1 and Pak6 as well. A cascade of phosphorylation from
PAK to LIMK to cofilin occurs, which inhibits cofilin’s actin severing activity and
reduces depolymerization of actin filaments (Carlisle and Kennedy, 2005; Schubert and
Dotti, 2007). Thus, our finding that FMRP targets encode proteins upstream to the
regulation of actin dynamics fits extremely well with dendritic spine biology of the
fragile X syndrome.
Moreover, many FMRP RNA targets are pre-synaptic cytomatrix proteins. Bsn,
Pclo, Munc13a are specifically localized in the active zone where neurotransmittercontaining vesicles (SVs) dock, fuse, release their content and then recycle. Bsn and Pclo,
two very large proteins structurally related and highly specifically localized near the site
of neurotransmitter release, are postulated to be members of the ensemble of proteins
orchestrating events at the active zone. Munc13a binds the second messenger
diacylglycerol (DAG). At increase concentration of DAG, Munc13 regulates the fusion
of SVs with plasma membrane. Munc13a binds SV-associated protein Doc2 and induces
the open conformation of syntaxin in the plasma membrane, thereby promoting the
formation of a loose SNARE complex for neurotransmitter release (Dresbach et al., 2001;
Schoch and Gundelfinger, 2006). Interestingly, syntaxin binding protein 1 (stxbp1 or
munc18) has also been CLIPed as a FMRP target. This is another example that FMRP
targets encode proteins that interact with one another. Yet another example is that
presynaptic Caskin1, Nrxn1, Cacna1e, Cacna1d, postsynaptic Nlgn, and PSD95, which
form a close network, have all been CLIPed as FMRP targets. CASK and MaGuK
(membrane associated guanylate kinase) family members in complex with Veli/Mint1 at
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the presynapse interact with presynaptic voltage caged Ca2+ channels and adhesion
molecule Nrxn. Nrxn binds postsynaptic adhesion molecule Nlgn, which in turn is linked
to the postsynaptic MAGUK, PSD95 (Dresbach et al., 2001; Schoch and Gundelfinger,
2006). Therefore, we find this theme that FMRP targets encode proteins forming an
interacting network at the synapse.
Presynaptic FMRP targets were initially surprising to us, since majority of
findings on fragile X biology focus on dendritic, postsynaptic abnormalities. Recently
FMRP has been shown to localize in developing axons of cultured hippocampal neurons
and growth cones had more filopodia and were less dynamic in Fmr1 null neurons (Antar
et al., 2006). Therefore, FMRP may have a broader role than we thought, having both
dendritic and axonal functions that converge at the developing synapse.
In conclusion, FMRP targets encoding coherent functions in cytoskeletal
organization and synaptic transmission fit extremely well with fragile X biology.
Misregulation of cytoskeletal proteins, cytoskeletal motor proteins, pre- or post-synaptic
proteins due to lack of FMRP can lead to distorted synaptic architecture and signaling,
causing dendritic spine phenotype (Comery et al., 1997; Nimchinsky et al., 2001) and
altered synaptic plasticity (Bear et al., 2004; Hou et al., 2006; Huber et al., 2002;
Koekkoek et al., 2005; Nosyreva and Huber, 2006) observed in fragile X patients and
mouse models.

Future Directions for validation of FMRP RNA targets
Knowing what set of RNAs FMRP binds to in vivo, we are interested in asking
what regulatory roles FMRP has on these targets. However, we have encountered a
hurdle. The precise physiological function of FMRP has not been defined. The most
plausible function of FMRP known to us so far is translational regulation. And the best
piece of evidence is that FMRP is associated with polyribosomes in cell culture and
mouse brain (Corbin et al., 1997; Feng et al., 1997a; Feng et al., 1997b; Khandjian et al.,
1996; Khandjian et al., 2004; Stefani et al., 2004). Validation for even the bestunderstood target, Mtap1b, is not trivial. Biochemically we cannot reproduce the change
of Mtap1b mRNA levels in polyribosomes (Brown et al., 2001), using different fragile X
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mouse models. Changes in protein levels has been shown to be very subtle (Li et al.,
2001).
Our validation assays have focused on assessing the translational status of FMRP
mRNA targets. The encoded protein levels are measured by Western blot and their
translational profiles over polyribosome gradients are assessed by quantitative RT-PCR.
We have attempted to validate these targets not only in wild type mice vs. Fmr1 knockout
mice, but also in Fmr1/FXR2 double knockout mice, considering the functional
redundancy of Fmr1 paralogs. However, we have not succeeded in detecting changes in
steady state protein levels, or steady state distribution of transcripts on polyribosome
gradients thus far. Continuing efforts will focus on developing new functional assays to
eventually validate these targets in animal models.

-Resolve Redundancy from autosomal paralogs
Although we are trying to overcome the functional redundancy of Fmr1 paralogs by
using Fmr1/FXR2 double knockout mice, the remaining FXR1P may still be able to
compensate for the loss of FMRP and FXR2P to a great extent, therefore, still
significantly attenuating the effect of lack of FMRP on its targets.
FXR1 mice die immediately after birth likely due to respiratory or cardiac failure
to due to their striated muscle defect (Mientjes et al., 2004). One way to overcome this is
to generate a conditional FXR1 knockout mouse model, so that Fmr1/FXR1/FXR2 triple
knockout mice can be obtained and used for validation. A more immediate solution is to
use siRNA pools to knockdown the expression of FMRP, FXR1P, and FXR2P in cell
lines or primary neurons, but the drawback is that tissue culture cannot mimic true in vivo
synapses or cell-cell signaling in brain. Another solution is to use Drosophila for
validation. A single homologue, dFXR, exists for all three mammalian FMRP family
members. Similar to Fmr1 knockout mice in many ways, dfxr mutant flies exhibit
increased synaptic growth and branching at the neuromuscular junction, impaired
coordinated behavior, arrhythmic circadian activity, and reduced courtship (Inoue et al.,
2002; Ishizuka et al., 2002; Morales et al., 2002; Zhang et al., 2001b). Significantly, the
futsch/Mtap1b mRNA and dFXR protein interaction was validated using Drosophila
genetics (Zhang et al., 2001b).
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-More approaches to assess mRNA trafficking and localized translation
Preliminary analysis of role of FMRP in trafficking and localized translation of its
mRNA targets has been done by examining protein levels in synaptoneurosome
preparation. No difference so far has been observed for a few synaptically localized
targets in wild type vs. Fmr1 knockout or Fmr1/FXR2 double knockout mice. Our
synaptoneurosome protocol is enriching for resealed pre- and post-synaptic vesicles;
however, it is far from pure. Currently available synaptoneurosome protocols suffer from
either impurity or low yields. Our lab has been generating BAC transgenic mice
expressing EGFP tagged Gabbr2, which is present in both excitatory and inhibitory
synapses. These mice can be a very useful tool toward getting purer synaptoneurosomes
by IP of tagged EGFP and can facilitate better validation of FMRP targets.
FISH to assess mRNA trafficking and immunofluorescence to examine localized
protein levels on either primary neuron culture or brain slices are also plausible
approaches to validate FMRP targets.
Our lab has also worked out a protocol for laser capture microdissection of
dendrites in layer I in cortex, and molecular layers in cerebellum, from their cell bodies.
This technology could be applied to wild type vs. Fmr1 knockout or Fmr1/FXR2 double
knockout mice. If FMRP were to regulate trafficking of mRNA to dendrites, we might be
able to observe a difference in mRNA levels in layer I or molecular layer between wild
type vs. knockout or double knockout mice. Instead of target-by-target approach,
microarray analysis of RNA present in these compartments can give us a more
comprehensive list that we can use to overlap with our CLIP target list. Some of the
mRNA changes, if any, could be from direct effect of FMRP on its target RNA while
others could be an indirect effect.
-FMRP functions could be activity dependent
Last but not least, activity-dependent changes in the functional interaction
between FMRP and the translational apparatus have been proposed by a number of
groups (Greenough et al., 2001; Hou et al., 2006; Huber et al., 2002; Muddashetty et al.,
2007; Weiler et al., 1997). Group I mGluR-dependent LTD is increased in hippocampal
and cerebellum slices of Fmr1 knockout mice and is no longer protein synthesis
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dependent (Huber et al., 2002; Koekkoek et al., 2005; Nosyreva and Huber, 2006). It is
likely that we need to incorporate activity into our various validation assays in order to
see an enhanced or transient effect of FMRP on its targets. Primary neuron cultures can
be treated with KCl or DHPG and brain slices can either be treated with DHPG or
stimulated with paired pulses before we perform our validation assays. Furthermore, our
lab has previously explored seizures induced in mice by MECS or pilocarpine treatment.
Preliminary data has shown that seizures altered mRNA localization in dendrites and
alternative splicing pattern of certain genes (O’Donovan, K, Wickiser, JK and Wang, H).
Furthermore, Fmr1 knockout mice were reported to be susceptible to audiogenic epileptic
seizures (Chen and Toth, 2001; Musumeci et al., 2000). Therefore, treatment of MECS or
pilocarpine can possibly help our validation assays by enhancing FMRP effects. If so, it
allows us to test our FMRP targets in mouse brain, the most physiologically relevant
system.
-An open mind for FMRP functions
FMRP may be a multi-functional protein, contributing to different steps of gene
expression. So far, a few functional roles have already been proposed, e.g., translational
regulation, including localized or via microRNAs, transport of mRNA, and mRNA
turnover. Anecdotally, we have observed FMRP targets to encode extremely large
proteins. Just to name a few of them; APC is 313kDa, Kif1a 186kDa, Kif1b 195kDa,
Mtap1b 271kDa, Macf1 488kDa, Bsn 434kDa, Pclo 550kDa, Akap6 255kDa, and Dst
592kDa. FMRP may function as a molecular chaperone, facilitate the folding of these
large proteins co-translationally. Moreover, FMRP, although largely cytoplasmic, does
have a NES and NLS signal. We thus far have focused on FMRP exonic CLIP tags, but
analysis of intronic CLIP tags enriched in wild type over Fmr1 knockout may cast light
on a nuclear role for FMRP.
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Gene Symbols
Aatk

Apoptosis-associated tyrosine kinase

Akap6

A kinase anchor protein

Apc

Adenomatosis polyposis coli

Arf3

ADP-ribosylation factor 3

Arhgap5

Rho GTPase activating protein 5

Bai2

Brain-specific angiogenesis inhibitor 2

Bsn

Bassoon

Cacna1d

Calcium channel, voltage-dependent, L type, alpha 1D subunit

Cacna1e

Calcium channel, voltage-dependent, R type, alpha 1E subunit

Camk2a

Calcium/calmodulin-dependent protein kinase II alpha

Dap-3

Disks large associated protein 3

Dnchc1

Dynein, cytoplasmic, heavy chain 1

Dncic1

Dynein, cytoplasmic, intermediate chain 1

Dst

Dystonin

Gabbr1

Gamma-aminobutyric acid receptor 1

Grin2a

Glutamate receptor, ionotropic, NMDA2A (epsilon 1)

Grin2b

Glutamate receptor, ionotropic, NMDA2B (epsilon 2)

Grip1

Glutamate receptor interacting protein 1

Hdh

Huntington disease gene homolog

Itsn

Intersectin

Kif1a

Kinesin family member 1A

Kif1b

Kinesin family member 1B

Kif5a

Kinesin family member 5A

Kif5c

Kinesin family member 5C

Lphn1

Latrophilin 1

Macf1

Microtubule-actin crosslinking factor 1

Mtap1b

Microtubule-associated protein 1 B

Munc13a

Mammalian homolog of Unc-13 A (C. elegans)

Myo5a

Myosin Va

Nlgn2

Neuroligin 2
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Nlgn3

Neuroligin 3

Nrxn1

Neurexin 1

Pak1

p-21 activated kinase 1

Pak6

p-21 activated kinase 6

Pclo

Piccolo

Plec1

Plectin 1

Psd95

Discs large homolog 4 (Drosophila)

Spnb2

Spectrin beta 2

Spnb3

Spectrin beta 3

Stxbp1

Syntaxin binding protein 1

Syn1

Synapsin 1

Syn3

Synapsin 3

Vamp2

Vesicle-associated membrane protein 2
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Figure 4.1. A schematic illustration of FMRP CLIP method. The diagram represents
the FMRP CLIP method adapted from (Ule et al., 2005a), described in detail in Chapter 2
Materials and Methods.
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Figure 4.2. Optimization of FMRP IP condition. (A) Western analysis of FMRP (1C3
antibody) in mouse brain lysates before and after ultracentrifugation at 60,000rpm vs.
30,000rpm spin (TLA 120.2 rotor), supernatant (S60K, S30K) vs. pellet (P60K, P30K).
At 60,000rpm, half of FMRP was lost to the pellet. At 30,000rpm, the majority of FMRP
was retained in the supernatant; and became the input to IP. (B) Testing various FMRP
specific antibodies for IP. Only 7G1-1 antibody was able to IP FMRP in 1XPXL buffer.
(C) Testing various IP parameters: dynal (D) vs. sepharose (S) beads, protein A (A) vs.
protein A and G mix (AG), with or without rabbit anti-mouse Fcγ bridging antibody,
7G1-1 ascites fluid (a) vs. monoclonal supernatant (s) and titration of 7G1-1 antibody.
Condition 3* (dynal protein A beads, 120ug bridging antibody, 8ul 5mg/ml 7G1-1 mouse
ascites) gave the best IP efficiency.
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Figure 4.3. FMRP CLIP. (A) Postnatal day 8 mouse brains were UV irradiated,
protein:RNA complexes IPed with FMRP specific 7G1-1 monoclonal antibody, RNA
ligated with 32P labeled 3’ linker, and complexes separated by SDS-PAGE, transferred to
nitrocellulose, and visualized by autoradiography. Either wild type (WT), Fmr1 knockout
(KO), or non-crosslinked wild type (noXL) brain lysates were used. CLIP performed
using wild type brain revealed radiolabeled signal from RNA-FMRP complexes at
molecular sizes greater than Mr of FMRP. RNA signal was much fainter from Fmr1
knockout sample and absent from non-crosslinked sample. (B) 7G1-1 IP under our
optimized condition was able to clear majority of FMRP while it did not IP or co-IP
FXR1P. (C) RNA-FMRP complexes were cut out from areas of the membrane boxed in
red from wild type sample. Proteins were digested. RNAs were RT-PCR amplified and
separated on a polyacrylamide gel. Bands from Fmr1 knockout and non-crosslinked
samples were processed in parallel but gave little signal.
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Figure 4.4. FMRP-RNA complexes migrate according to the sizes of the crosslinked
RNA tags. (A) P8 mouse brain FMRP CLIP autoradiograph. Bands corresponding to
different molecular weights of protein-RNA complexes were cut out from the membrane.
Excised areas are designated by a red box. (B) Optimized 7G1-1 IP condition depleted
the majority of FMRP. “Total” reflects the input to the IP, “S30K” is the supernatant after
a 30K spin and “S-IP” is the supernatant after IP. (C) RNAs were RT-PCR amplified and
separated by denaturing PAGE. Significantly the peak of RT-PCR product from the
bands excised from the gel in 4.4A increase in size with increasing Mr, as would be
expected for RNAs of increasing size crosslinked to a protein of constant size. Little RTPCR product is seen in the KO for the 85kDa, 95kDa and 115 kDa bands. The sharp band
of approximately 60 nts is seen in both WT and KO mice.
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Figure 4.5. The majority of FMRP CLIP tags are exonic. Out of 1698 unique FMRP
CLIP tags from the wild type sample, 66% were exonic hits, in comparison to only 27%
of exonic hits in Fmr1 knockout sample, which served as the background of our CLIP
experiment. Nuclear splicing factors, Nova and bPTB had 24% and 8% of exonic hits
respectively.
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Figure 4.6. FMRP CLIP tags distribute evenly along the length of mRNA. (A)
Number of cumulative FMRP tags were plotted against mRNA length. The distribution
was best fit for a linear regression with r2=0.99. (B) Plot of 31 tags on adenomatosis
polyposis coli (APC) mRNA, the top hit among our FMRP targets.
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Table 4.I. List of FMRP top mRNA targets from three independent CLIP
experiments (hits≥2), from P8 mouse brain. Genes are ranked according to their
enrichment in WT compared to KO (net WT exonic hits=WT-exonic hits minus KOexonic hits). Previously validated target in Drosophila, Mtap1b (Zhang et al., 2001b),
was one of our top targets. Rab6ip1, Spnb3, and Aatk on this list also overlapped with
previously identified FMRP targets (Brown et al., 2001). The last column “polysome
CLIP hits” tallies the results of one experiment on p25 mice using high-throughput
sequencing to identify RNA ligands crosslinked to FMRP on polysomes in brain. Total
brain FMRP targets overlapped well with polysome FMRP targets.

GeneSymbol
APC
Kif1a
Mtap1b
macf1
Adcy1
Pclo
Spnb3
Kif1b
Kif5a
Nlgn2

Hivep2
Akap6
Kif5c
Bsn
Fasn
Itpr1
Huwe1
Rab6ip1
Hdh
Phr1
Dst
Caskin1
1110007H17Rik
Igfbp5
Atp2b2
Ptprs
2610507B11Rik
BC067047
Aatk
Eef2
Grin2b
Abr
Grin2a
Myo5a
Ptprt
2900052E22Rik

GeneName
adnomatous polyposis coli
kinesin family member 1A
microtubule-associated protein 1 B
microtubule-actin crosslinking factor
1
adenylate cyclase 1
piccolo
spectrin beta 3
kinesin family member 1B
kinesin family member 5A
neuroligin 2
human immunodeficiency virus type
I enhancer binding protein 2
A kinase (PRKA) anchor protein 6
kinesin family member 5C
bassoon
fatty acid synthase
inositol 1,4,5-triphosphate receptor
1
HECT, UBA and WWE domain
containing 1
Rab6 interacting protein 1
Huntington disease gene homolog
PAM, HIGHWIRE, RPM 1
dystonin
CASK interacting protein 1
insulin-like growth factor binding
protein 5
ATPase, Ca++ transporting, plasma
membrane 2
protein tyrosine phosphatase,
receptor type, S

apoptosis-associated tyrosine kinase
eukaryotic translation elongation
factor 2
glutamate receptor, ionotropic,
NMDA2B (epsilon 2)
active BCR-related gene
glutamate receptor, ionotropic,
NMDA2A (epsilon 1)
myosin Va
protein tyrosine phosphatase,
receptor type, T

Net-WT WT- WTKOKO- Polysome
Exon Exon Intron exon intron CLIP hits
30
31
1
1
0
60
10
10
3
0
0
84
8

10

0

2

0
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6
5
5
5
4
4
4

7
5
5
5
4
4
4

1
0
0
0
0
0
0

1
0
0
0
0
0
0

0
0
0
0
0
0
0

7
101
26
24
61
54
28

4
4
4
3
3

4
4
4
3
3

1
0
0
0
0

0
0
0
0
0

2
0
0
0
0

24
24
17
110
46

3

3

1

0

1

39

3
3

3
3

0
0

0
0

1
0

33
32

3
3
3
3
3

3
3
3
3
3

0
1
0
0
0

0
0
0
0
0

0
1
0
0
0

31
23
17
15
7

3

3

0

0

0

1

2

2

0

0

0

65

2
2
2

2
2
2

1
0
0

0
0
0

0
0
0

52
39
33

2

2

0

0

0

33

2

2

0

0

0

33

2
2

2
2

1
0

0
0

0
0

32
29

2
2

2
2

0
1

0
0

0
0

26
24

2
2

2
2

1
0

0
0

0
0

19
19
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GeneSymbol
AA536749
Disp2

GeneName

Net-WT WT- WTKOKO- Polysome
Exon Exon Intron exon intron CLIP hits
2
2
1
0
0
17
2

2

0

0

0

16

2

2

0

0

0

15

2

2

0

0

0

15

2

2

0

0

0

14

2
2

2
2

0
0

0
0

0
0

14
13

Dnchc1
dynein, cytoplasmic, heavy chain 1
4930544G21Rik

2
2

2
2

0
0

0
0

0
0

12
12

4733401O11Rik
Ankrd12
ankyrin repeat domain 12-like
transformation/transcription domain
Trrap
associated protein
G protein-regulated inducer of
Gprin1
neurite outgrowth 1
A830007M12
GAMMA-AMINOBUTYRIC ACID
Gabbr1
(GABA-B) RECEPTOR, 1
solute carrier family 4 (anion
Slc4a3
exchange), member 3
D330037A14Rik

2
2

2
2

0
0

0
0

0
0

12
12

2

2

0

0

0

11

2
2

2
2

0
0

0
0

0
0

10
10

2

2

0

0

0

9

2
2

2
2

0
0

0
0

0
0

9
8

2

2

0

0

0

7

Scd2
stearoyl-Coenzyme A desaturase 2
9030205A07
0710001E19Rik

2
2
2

2
2
2

0
0
0

0
0
0

0
0
0

7
7
7

D630003G22Rik
2500002E12Rik
Arf3
ADP-ribosylation factor 3
Sez6l
seizure related 6 homolog like
Arhgap5
Rho GTPase activating protein 5

2
2
2
2
2

2
2
2
2
2

1
0
0
0
0

0
0
0
0
0

0
0
0
0
0

6
6
5
5
4

2

2

0

0

0

4

Nr3c1
4932408F19
1110037D04Rik
Ids
iduronate 2-sulfatase
ankyrin repeat and FYVE domain
Ankfy1
containing 1
Clcn4-2
chloride channel 4-2
Syn3
synapsin III

2
2
2
2

2
2
2
2

0
0
0
0

0
0
0
0

0
0
0
0

3
3
3
2

2
2
2

2
2
2

0
0
0

0
0
0

0
0
0

1
1
-

TPRD
tetratricopeptide repeat domain 3
Unc5c
UNC-5 homolog C
2410089E03Rik

2
2
2

2
2
2

0
0
0

0
0
0

0
0
0

-

Dbccr1

Slc22a12

Cacna1e
Odz3
2310014B11Rik

Itsn

Birc6

dispatched homolog 2 (Drosophila)
deleted in bladder cancer
chromosome region candidate 1
(human)
solute carrier family 22 (organic
anion/cation transporter), member
12
calcium channel, voltage-dependent,
R type, alpha 1E subunit
odd Oz/ten-m homolog 3
(Drosophila)

intersectin (SH3 domain protein 1A)

baculoviral IAP repeat-containing 6
nuclear receptor subfamily 3, group
C, member 1
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Table 4.II. GoMiner analysis of molecular functions of FMRP target genes with hits
≥2. The top 73 FMRP target genes were analyzed by the GoMiner program, using total
brain RNAs as a control set. For each gene ontology, the total number of genes in control
set and FMRP targets were shown. p values represented the significance of enrichment of
genes within gene ontologies of FMRP targets relative to the control group. p values
lower than 0.001, which represented the most significant enrichment, were marked in red.

GO categories
cytoskeleton dependent intracellular transport
cytoskeleton organization and biogenesis
microtubule based movement
transmission of nerve impulses
microtubule based processes
synaptic transmission
neurotransmitter secretion
cell-cell signaling
neurotransmitter secretion
regulated secretory pathway
organelle organization and biogenesis
regulation of neurotransmitter levels
cellular metabolism
cellular biogenesis
transcription
DNA repair
signal transduction
cell cycle
cell death
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total genes FMRP CLIP
(out of
target
8169 brain
genes
RNA)
(hit>1)
enrichment p value
82
8
13.9
8.0E-08
445
15
4.8
2.1E-07
70
7
14.2
4.7E-07
328
12
5.2
1.9E-06
170
9
7.5
2.2E-06
291
10
4.9
2.7E-05
526
13
3.5
4.7E-05
495
12
3.4
1.2E-04
79
5
9.0
2.1E-04
82
5
8.7
2.5E-04
1008
17
2.4
3.2E-04
109
5
6.5
9.4E-04
4472
22
0.7
1.0E+00
934
5
0.8
8.0E-01
1305
7
0.8
8.4E-01
185
1
0.8
7.3E-01
1954
22
1.6
8.6E-03
721
6
1.2
4.0E-01
589
6
1.4
2.3E-01

Figure 4.7. FMRP target genes encoding coherent functions. Relative representation
of selected molecular functions (as defined by GoMiner) for the total set of genes in
mouse brain and 73 FMRP CLIP targets (hits ≥2), illustrating coherent functions of
FMRP bound mRNA targets (* indicates p<0.001).
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Table 4.III. List of representative FMRP targets in their function categories.
Grouping of FMRP CLIP targets was determined by GoMiner and published literature.
Genes listed in bold had hits ≥2.
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Figure 4.8. FMRP targets encode proteins that interact with one another forming a
network at the synapse. Shaded genes were FMRP CLIP targets, pink color for targets
expressed at presynapse while blue color for postsynaptically expressed targets.
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Figure 4.9. Kif5A protein levels showed no significant difference in wild type vs.
Fmr1 knockout mouse brains. Western blot and quantification of (A) P8, P14, and P40
cortex, (B) P8, P14, and P40 cerebellum, (C) P40 diencephalon, brain stem,
hippocampus. Chemiluminescence was quantified using Versa Doc imaging, Kif1A
signal was normalized to loading control γ-tubulin. The same Western analysis was
applied to APC, Kif5a, Akap6, Grin2b, and Munc13 and no significant difference in their
protein levels was observed (data not shown).
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Figure 4.10. Translational profiles of a few FMRP target mRNAs were not
significantly different between wild type vs. Fmr1 knockout polyribosome gradients.
Wild type and knockout mouse brain cytoplasmic lysates were centrifuged on a w/w 2050% linear sucrose gradients. Gradients were fractionated and RNAs were collected from
each fraction. Quantitative RT-PCR was performed (ΔΔCt method) for each mRNA
target. Relative mRNA levels in each fraction were plotted as a percentage of the total of
a given mRNA to illustrate its distribution over the polyribosome gradient. GAPDH (A)
was the control mRNA that did not show distribution changes over wild type vs.
knockout polyribosome gradient. (B) APC mRNA, (C) Mtap1b mRNA, (D) Rab6ip
mRNA, (E) Kif5c mRNA, (F) Arhgap5 mRNA.
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Figure 4.11. Translational profile of Mtap1b mRNA was not significantly different
between wild type vs. I304N knock-in polyribosome gradients. Wild type and I304N
mouse brain cytoplasmic lysates were centrifuged on w/w 20-50% linear sucrose
gradients. Gradients were fractionated and RNA was collected from each fraction.
Quantitative RT-PCR was performed (ΔΔCt method) for Mtap1b mRNA (A). Relative
mRNA levels in each fraction were plotted as a percentage of the total mRNA to
illustrate its distribution over the polyribosome gradient. GAPDH (B) was the control
mRNA that did not show distribution changes over wild type vs. I304N polyribosome
gradient.
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Figure 4.12. Protein levels of Kif1a, Kif5a, Grin2b were not significantly different in
wild type vs. Fmr1/FXR2 double knockout mouse brains. Western blot and
quantification of (A) Kif1a, (B) Kif5a, and (C) Grin2b expression in P8 hippocampus;
WT n=7 and DKO n=5. Additional targets APC, Akap6, and Munc13 were subject to the
same Western analysis and no significant difference in their protein levels was observed
(data not shown).
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Figure 4.13. A few synaptically localized FMRP targets had similar expression levels
in wild type vs. Fmr1 knockout synaptoneurosomes. (A) Synaptoneurosome
preparation enriched NR1, Camk2a, and synaptophysin, while the glial marker GFAP
was depleted, shown by Western blot. (B) Akap6, (C) Munc13, (D) Camk2a expression
in synaptoneurosomes prepared from P15 wild type vs. Fmr1 knockout mice revealed no
difference. Expression levels of these targets were also examined in wild type vs. double
knockout synaptoneurosomes and no significant difference was found (data not shown).
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CHAPTER V. COMPARISON OF ARGOUNATE BOUND
miRNAs IN WILD TYPE AND Fmr1-NULL MOUSE
BRAINS
Introduction
We have become interested in miRNAs because several reports have linked
FMRP to the RNA-induced silencing complex (RISC). In Drosophila, dFXR has been
found to interact biochemically with Argonaute 2 (dAgo2) (Caudy et al., 2003; Caudy et
al., 2002; Ishizuka et al., 2002) and genetically with Argonaute 1 (dAgo1) (Jin et al.,
2004). In mammalian cell culture, FMRP and FXR1P have been shown to coimmunoprecipitate with mAgo2, the mammalian ortholog of dAgo1 (Jin et al., 2004;
Vasudevan and Steitz, 2007). These findings suggest that there may be a connection
between the functions of FXR family members and miRNA involved processes.
MicroRNAs (miRNA) are a class of evolutionarily conserved non-coding RNA
sequences of approximately 22 nts. They play an important role in regulating translation
and degradation of mRNAs through base pairing to sites that are partially complementary
on mRNAs. miRNA genes are often located in clusters that are transcribed by RNA
polymerase II or III as polycistrons (Borchert et al., 2006; Lee et al., 2004). Primary
miRNA transcripts (pri-miRNAs) are cleaved by RNase III enzyme, Drosha, liberating
stem loop structured precursors (pre-miRNAs) of roughly 70 nucleotides in length (Lee et
al., 2003). Pre-miRNAs are exported out of the nucleus via Exportin 5 in a Ran-GTP
dependent manner (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2003). In the
cytoplasm, pre-miRNAs are further processed by another RNase III enzyme, Dicer, to
produce a shorted-lived double-stranded miRNA/miRNA* complex of 22 nucleotides
composed of one guide strand, the mature miRNA, and one passenger strand, miRNA*
(Lee et al., 2002; Park et al., 2002). Following cleavage, RDE-4/R2D2 facilitates the
transfer of miRNA/miRNA* to the RISC complex, which is the effector complex of
miRNA action and is composed of Argonaute proteins and a number of accessory factors.
The passenger strand, miRNA*, is cleaved quickly and is subsequently degraded
(Matranga et al., 2005). The remaining mature miRNA recognizes complementary
binding sites located in 3’UTRs of target mRNAs and functions as a guide for effectors,
103

such as Argonaute proteins, to regulate mRNA stability or repress translation (Pillai et al.,
2007).
Although several reports have shown interactions of FMRP with Argonautes
through biochemical assays and Drosophila genetics, it is largely unknown whether
FMRP has any role on miRNA maturation, Argonaute loading, guidance of RISC effector
complex to mRNA, or miRNA mediated regulation of gene expression. Through a
serendipitous discovery during our study on the RNA binding properties of FMRP, we
found that a commercially available FMRP antibody, 7G1-1, was contaminated by a panArgonaute antibody. Using this antibody and CLIP methodology, we successfully cloned
Argonaute bound miRNAs from mouse brains. Preliminary data showed similar miRNA
expression in wild type vs. Fmr1 knockout mouse brains, consistent with Landgraf et al.
(Landgraf et al., 2007), suggesting that FMRP likely does not play a role in miRNA
maturation or miRNA:Ago assembly.

Characterization of FMRP 7G1-1 antibody
We found that a commercially available FMRP antibody, 7G1-1, was able to
immunoprecipitate Argonaute proteins during the troubleshooting for the FMRP-CLIP
experiment. After covalently crosslinking RBPs to their RNA targets using ultraviolet
light, multiple steps of stringent purification can be used for the purification of RBPRNA complexes and non-crosslinked free RNA is “filtered” out. When we used the 7G11 antibody, we observed there were still some RNA signals in the Fmr1 knockout sample
concentrated at approximately 115 kDa (Figure 5.1). Therefore, we analyzed the purity
of 7G1-1 immunoprecipitates with protein staining, and the protein bands were identified
with mass spectrometry (Figure 5.2). As we expected, FMRP (band 1) was
immunoprecipitated from wild type while absent from Fmr1 knockout brains. To our
surprise, 7G1-1 antibody also was able to immunoprecipitate Argonautes 1 to 4 (band 4).
We confirmed the mass spectrometry result by Western analysis; 7G1-1 antibody
immunoprecipitated Argonaute1 and Argonaute2 from wild type, I304N knock-in, and
Fmr1 knockout mouse brain lysates (Figure 5.3A). Since the Argonaute proteins were
immunoprecipitated in the absence of FMRP, we speculated that the 7G1-1 antibody we
used for our experiments recognized Argonaute proteins directly, instead of co104

immunoprecipitating them. As a negative control, another FMRP antibody, 17722, did
not immunoprecipitate Argonaute proteins under the same conditions (Figure 5.3B). We
further confirmed the direct reactivity of 7G1-1 antibody to Argonautes by
immunoprecipitating recombinant Ago2 protein from crude bacterial lysates (Figure
5.3C).
There are two possibilities for the 7G1-1 antibody to recognize Argonaute
proteins. 7G1-1 could cross-react with the Argonautes, or it could be contaminated with
an unknown source of anti-Ago antibody. We distinguished these two possibilities by
blocking 7G1-1 immunoprecipitation using a competing peptide, the 15 amino acid
epitope of FMRP (Brown et al., 2001; Ceman et al., 2003b). The peptide successfully
competed away FMRP immunoprecipitation, but has no effect on Ago protein
immunoprecipitation (Figure 5.4A). Our data suggests that FMRP and Argonautes do not
share the same 7G1-1 epitope. Instead, this specific batch of commercial 7G1-1 may not
be a true monoclonal, but a mixture of two antibodies, one for FMRP and the other for
the Argonautes. Indeed, a batch of 7G1-1 antibody obtained from Dr. Stephanie Ceman
no longer recognized Ago proteins (Figure 5.4B).

miRNA CLIP
Utilizing

CLIP

methodology

and

the

7G1-1

antibody

which

also

immunoprecipitates Argonaute proteins, we not only cloned FMRP-bound mRNAs, but
we also serendipitously cloned Argonaute-bound miRNAs from mouse brain. CLIP
experiments on Nova have demonstrated that RNA-protein complexes run quite true to
size on SDS-PAGE gels. For example, RNA-protein complexes that contain RNAs of
between 50-70 nts run approximately15-20 kDa larger than the Mr of the protein alone
(Ule et al., 2005a). We excised a few thin bands corresponding to molecular weights of
85, 90, 95, and 115 kDa from both wild type and Fmr1 knockout samples (Figure 4.4A
in Chapter IV). After RT-PCR amplification, nucleic acid (NA) signals were present in
wild type and very little in FMR-1 knockout sample. As the size of RNA-protein
complexes increased from 90 to 95 kDa, NA smears also increased in size (Figure 4.4C
in Chapter IV). The average size of RNAs cloned from 90 and 95 kDa corresponded
well with the expected size of RNAs directly crosslinked to FMRP. However, 115 kDa
105

generated sharp NA bands present in both wild type and Fmr1 knockout samples. The
sizes of these NAs were unexpectedly small, approximately 55-60 nts in length,
corresponding to original RNA tags of 19-24 nts plus linkers totaling 36 nts. Taken
together with the finding that the 7G1-1 antibody was contaminated with a panArgonaute antibody, these small RNAs from 115 kDa are most likely crosslinked to
Argonautes. The uniform length of the NAs indicated that they could be miRNAs, which
was confirmed by cloning and sequencing. More than 80% of the RNAs corresponding to
115 kDa were matched to known miRNAs in the miRNA registry. miR-124a, miR-30c,
and let-7 were the three miRNAs that were the most frequently cloned in P8 mouse
brains (Table 5.I). Assuming the number of tags sequenced is reflective of the
abundance, our data suggests that they are likely the most abundant mouse brain miRNAs
at postnatal day 8.
We then attempted to compare miRNA expression in wild type vs. Fmr1
knockout mouse brains. Preliminary data from ~350 sequenced miRNAs showed that the
top most abundant miRNAs have similar expression in wild type vs. Fmr1 knockout
brains (Table 5.I). In order to draw a definitive conclusion, we needed a larger set of
sequences. A repeat of the Ago CLIP experiment using P16 mouse brains was submitted
for high throughput sequencing. 198,236 sequences were obtained from Fmr1 knockout.
Of these, 165,168 were matched to known miRNAs. Unfortunately, due to sequencing
errors, only 2706 sequences from wild type, 2275 of which were matched to known
miRNAs, were obtained. Our data showed that the frequencies of miRNAs CLIPed were
largely similar between wild type and knockout mouse brains, consistent with Landgraf
et al. (Table 5.II) (Landgraf et al., 2007). However, the disparity in the total numbers of
these two data sets and the low number of sequences obtained from the wild type set
prevented us from drawing a definitive conclusion at present. The sequencing of wild
type miRNA sample would need to be repeated. On the other hand, the expression
patterns of miRNAs at P8 and P16 were found to be different. For instance, miR-124a
was found to be the most abundant miRNA consisting of ~30% of total miRNAs obtained
at P8 in both wild type and Fmr1 knockout brains, but it represented only ~3-6% of total
miRNAs in P16 mouse brains, suggesting miRNA expression may be developmentally
regulated.
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Conclusion
Taking advantage of an antibody that unexpectedly immunoprecipitates
Argonaute proteins, we have extended CLIP methodology to the purification of miRNAs,
and we have demonstrated that miRNAs are directly bound to Argonaute proteins.
Furthermore, since more than 80% of the sequences cloned from Argonaute CLIP match
to known miRNAs, we have confirmed the high specificity of CLIP methodology for the
purification of bona fide RNA targets bound to RNA binding proteins. Although the
remaining sequences have not been matched to known miRNAs so far, more analysis will
be done for the identification of new miRNAs. The two Argonaute CLIP experiments on
mouse brains from two developmental ages, P8 and P16, have shown different miRNA
expression patterns, consistent with Neilson et al. (Neilson et al., 2007), suggesting that
miRNA expression is dynamically regulated at different developmental stages.
Furthermore, our preliminary data have shown that miRNA expression is largely similar
in wild type and Fmr1 knockout mouse brains, indicating FMRP probably does not play a
role in miRNA maturation or miRNA-Ago assembly. Whether FMRP has a role in the
later processes, such as facilitating mRNA cognition or miRNA mediated regulation of
gene expression, will be a very interesting area of study for future exploration.
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Figure 5.1. Autoradiograph of FMRP CLIP shows unexpected RNA signals in Fmr1
knockout sample. Postnatal day 8 wild type (WT) and Fmr1 knockout (KO) mouse
brains were UV irradiated, protein:RNA complexes immunoprecipitated with FMRPspecific 7G1-1 monoclonal antibody, RNA-ligated with 32P labeled 3’ linker, and
separated by SDS-PAGE, transferred to nitrocellulose, and visualized by
autoradiography. CLIP performed using wild type brain revealed radiolabeled signals
from RNA-FMRP complexes. However, we still observed RNA signals in the Fmr1
knockout sample, with most intensity at ~115 kDa.
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Figure 5.2. Protein staining and mass spectrometry identify that 7G1-1 antibody
immunoprecipitates Argonaute proteins. Wild type and Fmr1 knockout brain lysates
were immunoprecipitated under FMRP CLIP condition. Immunoprecipitates were run on
a 4-12% Tris-glycine protein gel, stained with Coomassie stain (A) and followed with
silver stain (B). Triplet protein bands (band 1), which corresponds to Mr of FMRP, were
observed in wild type, but not in knockout, immunoprecipitates. Mass spectrometry
confirmed it was FMRP. Band 4 was identified as Ago proteins 1-4, present in both wild
type and Fmr1 knockout immunoprecipitates. Details of MS identification are listed in
(C).
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Figure 5.3. Confirmation that 7G1-1 recognizes Argonaute proteins. (A) Wild type
(WT), Fmr1 knockout (KO), and I304N knock-in (I304N) mouse brain lysates were IPed
with 7G1-1 antibody under FMRP CLIP condition. Immunoprecipitates were analyzed by
Western for FMRP, probed with 2F5 antibody, Argonaute 1 and Argonaute 2. (B)
Immunoprecipitation was done under the same conditions with another FMRP antibody,
rabbit polyclonal 17722, and Western analysis showed that 17722 did not
immunoprecipitate Argonaute 1 or Argonaute 2, in contrast to 7G1-1 antibody. (C)
Recombinant T7-tagged human Argonaute 2 (obtained from Addgene) or empty T7
vector were expressed in BL21 E coli. Bacteria were lysed with Bugbuster mastermix.
Lysates were sonicated and pelleted at 27,200xg to separate soluble proteins from
inclusion bodies. 7G1-1 antibody was able to immunoprecipitate recombinant Argonaute
2 protein, detected by Western blot probed with a T7 antibody. As negative controls,
7G1-1 immunoprecipitation from the bacterial lysate of the empty T7 vector and
immunoprecipitation using only beads did not generate any signal.
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Figure 5.4. “7G1-1” is contaminated with an unknown source of Argonaute
antibody. (A) 7G1-1 antibody was pre-incubated with 20ug, 200ug or 2mg (50 fold
excess) of FMRP 354-KHLDTKENTHFSQPN-368 peptide, the epitope 7G1-1
recognizes (Brown et al., 2001; Ceman et al., 2003b), or an irrelevant FLAG peptide.
FMRP peptide, but not FLAG peptide, was sufficient to completely block FMRP
immunoprecipitation from mouse brain. FMRP peptide even at 2mg had no effect on
Argonaute 1 or Argonaute 2 immunoprecipitation. (B) Original batch of 7G1-1 antibody
immunoprecipitate Arogounate 1 or Argounate 2 from mouse brain.
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Table 5.I. List of miRNAs cloned from Argonaute CLIP using P8 wild type vs. Fmr1
knockout mouse brains. miRNAs were listed for both wild type and Fmr1 knockout
according to the number of times being sequenced. The percentage as the total was
calculated for top ranked miRNAs.
mature miR
miR-124a
miR-30c
let-7 family
miR-9
miR-434
miR-487
miR-125b
miR-125a
miR-26a, b
miR-376a, b
miR-204
miR-300
miR-126-3p, 5p
miR-127
miR-219
miR-323
miR-99b
miR-137
miR-187
miR-193
miR-296
miR-485
miR-541
miR-138
miR-142-3p
miR-181a
miR-19b
miR-23b
miR-27a, b
miR-30a
miR-30b
miR-30e
miR-346
miR-384
miR-433
miR-484
miR-92
miR-100
miR-132
miR-135a
miR-139
miR-141
miR-143
miR-150
miR-151
miR-154
miR-16
miR-199a
miR-20
miR-301
miR-30d
miR-326
miR-328
miR-33
miR-337
miR-339
miR-350
miR-351
miR-369
miR-409
miR-429
miR-451
miR-540
miR-93
miR-466
total

WT
46
14
5
9
5
8
2
5
6
2
4
0
2
1
2
1
0
3
1
1
1
1
2
1
0
0
0
2
1
1
1
1
2
2
0
1
2
0
1
1
2
1
0
1
1
0
0
0
1
0
1
1
0
0
1
0
0
1
0
1
0
1
0
1
0
150

FMR1
KO
62
25
14
8
10
7
8
3
2
4
1
5
2
3
2
3
4
0
2
2
2
2
1
1
2
2
2
0
1
1
1
1
0
0
2
1
0
1
0
0
0
0
1
0
0
1
1
1
0
1
0
0
1
1
0
1
1
0
1
0
1
0
1
0
1
200

WT (%
total)
30.9
9.4
3.4
6.0
3.4
5.4
1.3
2.5
3.0
1.0

FMR1 KO
(% total)
31.2
12.6
7.0
4.0
5.0
3.5
4.0
1.5
1.0
2.0
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Table 5.II. List of top 35 miRNAs cloned from Argonaute CLIP using P16 wild type
vs. Fmr1 knockout mouse brains.
miRNAs P16 brains
mmu-mir-30e
mmu-mir-30d
mmu-mir-27a
mmu-mir-26a
mmu-mir-30a
mmu-mir-708
mmu-mir-124a
mmu-mir-181a
mmu-mir-9-1
mmu-let-7i
mmu-mir-181b
mmu-mir-138
mmu-let-7c-2
mmu-let-7b
mmu-mir-449
mmu-mir-344
mmu-mir-22
mmu-mir-153
mmu-mir-324
mmu-mir-27b
mmu-mir-101b
mmu-mir-34a
mmu-mir-16
mmu-let-7g
mmu-mir-221
mmu-mir-125b
mmu-mir-31
mmu-mir-383
mmu-mir-106b
mmu-mir-21
mmu-mir-136
mmu-mir-101a
mmu-mir-30c
mmu-mir-338
mmu-mir-340

KO hits
24230
16878
14248
11062
10998
10077
9110
6332
6056
3772
3320
3156
2866
2395
2215
1775
1590
1305
1156
1042
896
825
811
785
781
778
745
698
691
640
617
604
546
526
525

WT hits
397
297
163
287
197
92
67
71
68
57
37
17
32
21
23
15
10
21
5
15
5
10
10
6
6
20
11
11
5
4
6
2
4
4
6
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KO(%)
14.7
10.2
8.6
6.7
6.7
6.1
5.5
3.8
3.7
2.3
2.0
1.9
1.7
1.5
1.3
1.1
1.0
0.8
0.7
0.6
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.4
0.4
0.4
0.4
0.4
0.3
0.3
0.3

WT(%)
17.5
13.1
7.2
12.6
8.7
4.0
2.9
3.1
3.0
2.5
1.6
0.7
1.4
0.9
1.0
0.7
0.4
0.9
0.2
0.7
0.2
0.4
0.4
0.3
0.3
0.9
0.5
0.5
0.2
0.2
0.3
0.1
0.2
0.2
0.3

KO rank WT rank
1
1
2
2
3
5
4
3
5
4
6
6
7
9
8
7
9
8
10
10
11
11
12
17
13
12
14
14
15
13
16
18
17
23
18
15
19
34
20
19
21
35
22
24
23
25
24
30
25
31
26
16
27
20
28
21
29
36
30
38
31
32
32
65
33
39
34
40
35
33

CHAPTER VI. GENERAL DISCUSSION
This thesis is devoted to the understanding of functional roles of FMRP in normal
neuronal development and in the pathogenesis of the Fragile X Syndrome. Particularly
we have focused on the study of FMRP RNA binding properties, using both mouse
models and biochemical analysis. We have generated and characterized mouse models of
a functionally important point mutation in FMRP KH-type RNA binding domain that
recapitulate the fragile X phenotype. We have biochemically purified a reliable set of
FMRP RNA targets of coherent biological functions related to cytoskeletal organization
and synaptic transmission. Our data suggest RNA binding is a key function of FMRP,
through which it controls gene expression of a defined set of mRNA targets to mediate
normal cognition.

Point mutation mouse models of the Fragile X Syndrome reveal KH2
domain specific RNA binding is a key function of FMRP
Characterization of dysfunctional genes at the molecular level has unraveled the
causes of many diseases in the recent years. Naturally occurring mutations found in
patients, particularly point mutations that often define the loss of an important functional
domain, have facilitated the understanding of the pathogenesis of many diseases. For
instance, frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) is associated with mutations of the Tau protein. Thirty-nine mutations in Tau have
been identified with majority of them present in its coding region. Most mutations are
located in the microtubule-binding region, defining it as an important domain for Tau to
mediate microtubule assembly. There are also mutations in the N-terminus of Tau, a
domain that is found to be responsible for Tau trafficking and compartmentalization (van
Swieten and Spillantini, 2007). Another example is autosomal recessive juvenile
parkinsonism (ARJP). Mutations of Parkin (PARK2) are the predominant cause of the
disease. At least ten familial-associated Parkin mutations have been reported and they are
closely associated with the disruption of Parkin protein solubility, localization or
ubiquitination (Wood-Kaczmar et al., 2006).
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Fragile X Syndrome is one of the pioneer examples of one mutation being
responsible for one disease. In most cases the disease is caused by the CGG repeat
expansion in the 5’UTR of the Fmr1 gene and methylation of CpG islands that lead to
subsequent loss of FMRP expression (Jin and Warren, 2000, 2003; O'Donnell and
Warren, 2002). Conventional Fragile X DNA tests are designed to detect the triplet repeat
expansion in the 5’UTR of the gene, and as a result of that, there is only one missense
mutation found in a single patient known to us to this day. This single severely affected
patient harbors a conserved I->N mutation (I304N) within the KH2 RNA binding domain
(DeBoulle et al., 1993). Nevertheless this clinical case has offered us hope of focusing
FMRP studies in a key functional domain. This I->N mutation has previously been
shown to abolish RNA binding by this and similar KH domains (Lewis et al., 2000; Liu
et al., 2001; Ramos et al., 2003). Symptoms in this patient therefore suggest that the
disease is caused by a loss of FMRP KH2 domain specific RNA binding. However, this
interpretation has been complicated by questions of whether such a mutation might lead
to an unfolded protein that is completely functionless (Lewis et al., 1999; Musco et al.,
1997; Musco et al., 1996) rather than a correctly folded protein (Liu et al., 2001;
Pozdnyakova and Regan, 2005), in which RNA binding function is specifically lost.
Moreover, one case of a single patient who also has a confounding liver disease
(DeBoulle et al., 1993) limits us to draw any definitive conclusions.
To address these questions, we have introduced this mutation in mouse models
and phenocopied the disease. I304N knock-in mice have FMRP null-like behavioral
deficits and altered synaptic plasticity. The mutant protein is present, albeit at somewhat
reduced levels in adult mice. The protein retains some normal activities, as it is
competent to bind both protein partners such as FXR1 and FXR2 and, via its RGGdomain, to G-quartet RNA (Darnell et al., 2001), confirming it is not a completely
functionless denatured protein. However, I304N protein is defective in RNA binding, as
we have predicted, and is dissociated from polyribosomes, hence proper translational
control is likely lost in the I304N mouse brain. We have not been able to examine
homodimerization of the I304N protein in mouse brain, which has been reported to be
defective using ZZ-tagged recombinant protein (Laggerbauer et al., 2001b). This study
using fusion proteins may or may not correctly depict in vivo interactions. Our findings
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that mouse brain I304N FMRP is capable of heterodimerization with FXR1P and FXR2P
and is in a RNase resistant particle significantly larger than the monomer size suggest the
N-terminal protein interaction domain, NDF or PPId (Mazroui et al., 2003; Ramos et al.,
2006), may be unaffected by the mutation and direct protein-protein interaction may be
retained. The loss of polyribosome association is likely primarily due to a loss of KH2
domain specific RNA binding. Taken together I304N knock-in mice bearing a Fmr1-nulllike phenotype, our findings support the suggestion that a key function of FMRP in
mediating normal cognition is KH2 domain sequence specific RNA binding.
This I304N patient and our mouse models also point to the need for more
thorough and inclusive diagnostic tests, like DNA tests for detection of mutations in the
Fmr1 coding region or antibody staining for peripheral blood smears. Therefore more
potential candidates of Fragile X Syndrome can be correctly diagnosed and clinically
managed. In return, clinical cases of patients who have mutations that have not been
previously identified can supply new information for the understanding of the disease.
Moreover, our I304N knock-in mouse, in addition to the Fmr1 null, conditional
null mice, and Fmr1/FXR2 double knockout mice, is a new mouse model for the Fragile
X Syndrome. It can be used together with wild type and Fmr1 knockout mice for
validation assays to test RNA metabolism mediated by FMRP functions. Lastly, trials of
clinical treatment can also be tested on these mice, since the mice provide a
physiologically relevant living system that closely resembles fragile X patients.

FMRP may spatially and temporally regulate a coherent set of mRNAs
in a precise, robust and instantaneous fashion
Since the study of I304N mouse models suggests that a critical function of FMRP
is mediating sequence-specific RNA binding, the need to identify RNA ligands for
FMRP is heightened. Many laboratories have attempted various approaches (Brown et
al., 2001; Chen et al., 2003; Darnell et al., 2005a; Darnell et al., 2001; Dolzhanskaya et
al., 2003; Miyashiro et al., 2003; Muddashetty et al., 2007; Sung et al., 2003; Todd et al.,
2003; Xu et al., 2004; Zalfa et al., 2003; Zhang et al., 2001b). A long list of RNA
candidates has been generated. However, due to some intrinsic uncertainties underlying
each technique, these targets have limited overlap, making it difficult to distinguish true
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FMRP targets from falsely identified ones. To overcome this, our laboratory has
developed in vivo UV crosslinking and immunoprecipitation (CLIP) analysis (Ule et al.,
2005a; Ule et al., 2003). It has been used successfully to identify the genome-wide
binding sites for Nova family members on pre-mRNAs (Ule et al., 2003; Ule et al.,
2006).
We have successfully adapted CLIP methodology for FMRP and identified a
reliable list of mRNAs bound by FMRP, including previously validated Mtap1b mRNA
(Brown et al., 2001; Zhang et al., 2001b). This defined set of RNA targets encodes
proteins of coherent functions, such as cytoskeletal organization and synaptic
transmission, suggesting FMRP may regulate cytoskeletal dynamics, dendritic and axonal
functions that all converge at the developing synapse. Knowing what set of RNAs FMRP
binds to in vivo, we were interested in asking what regulatory roles FMRP has on these
targets. Given the sum of the current literature in the field, the most likely function of
FMRP on these RNA targets is in translational regulation, perhaps coupled with delivery
of mRNAs to neuronal processes. Binding and regulating gene expression of this defined
set of RNA targets is likely a key function of FMRP. We propose FMRP may spatially
and temporally fine-tune gene expression of its mRNA targets, but the regulation is
precise, robust and instantaneous.
Gene expression in a living system especially in highly specialized cells like
neurons is very complex, but precise. Knowing what mRNAs FMRP binds to, we
propose two modalities that may help to achieve precise and robust means of regulation.
First, many mRNAs FMRP binds encode proteins within the same functional category.
One example is that a few FMRP mRNAs encode cytoskeletal motor proteins.
Microtubule plus-end directed kinesins, Kif1a, Kif1b, Kif5a, and Kif5c, microtubule
minus-end directed dyneins, Dnchc1, and Dncic1, and actin based motor, Myo5a have all
been identified to be bound by FMRP. Therefore FMRP may regulate them in parallel
pathways, which can provide redundancy. A second modality is that FMRP regulates
mRNA targets encoding proteins in a network. For example, presynaptic Caskin1, Nrxn1,
Cacna1e, Cacna1d, postsynaptic Nlgn, and Psd-95 closely interact with one another and
have all been identified as FMRP targets. CASK and MAGUK (membrane associated
guanylate kinase) family members at the presynapse, in complex with Veli/Mint1,
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interact with presynaptic voltage-caged Ca2+ channels and adhesion molecule Nrxn. Nrxn
binds postsynaptic adhesion molecule Nlgn, which in turn is linked to postsynaptic
MAGUK, PSD-95 (Dresbach et al., 2001; Schoch and Gundelfinger, 2006). When FMRP
regulates targets within a network, individual components may be fragile in their
responsiveness to changes, but due to their interconnection, the entire network functions
synergistically and is highly resistant to perturbations. Therefore, FMRP achieves a
robust and precise regulation of gene expression in the nervous system.
Our data also show FMRP binds all over mature mRNAs, without preference for
UTRs or coding sequences, suggesting that FMRP likely does not inhibit translation
initiation, or else one would expect most of the CLIP tags to be found in the 5’UTR or
near the initiator methionine. FMRP has been shown to associate with polyribosomes
(Corbin et al., 1997; Feng et al., 1997a; Feng et al., 1997b; Khandjian et al., 1996;
Khandjian et al., 2004; Stefani et al., 2004). Even after puromycin treatment, FMRP cosedimented with the largest remaining polyribosomes containing three to four ribosomes
rather than with the much more prominent peak of monomeric ribosomes (Stefani et al.,
2004). These findings together with our data suggest that FMRP is more likely to
modulate translation at the step of elongation. Regulation at the elongation step confers
several advantages. First, since the elongation step is the most energy-consuming step of
translation, regulation at elongation likely acts as the final checkpoint for inhibiting
unwanted protein synthesis to conserve energy expenditure. Second, regulation at
elongation allows translation to pause or resume rapidly, because when the elongation
step is regulated, polyribosomes are still retained, which will allow translation to resume
rapidly. Fast translational control may be particularly important for neurons to respond to
a synaptic stimulus. FMRP has been shown to regulate the translation of synaptically
localized proteins in response to mGluR signaling. (Muddashetty et al., 2007). mGluRdependent LTD is enhanced in fragile X mouse models (Huber et al., 2002; Koekkoek et
al., 2005). In steady state, FMRP may suppress protein synthesis to conserve the energy
for more important use; but in response to a synaptic stimulus, FMRP bound mRNAs that
are already

associated

with

polyribosomes

and

translational

machinery

can

instantaneously resume translation, bypassing the rate limiting initiation step. Therefore,
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FMRP instant control of translation in response to a stimulus can be crucial for synaptic
plasticity.
Furthermore, lack of FMRP does not alter the global translational status, as the
polyribosome profile is unchanged in Fmr1 null mice. Using assays like Western blots to
examine protein levels and quantitative RT-PCR to examine mRNA translation profile
over polyribosomes, we haven’t been able to validate any FMRP mRNA targets. A
genome wide screen by microarray analysis has revealed no significant difference in the
levels of polyribosome associated mRNAs between wild type and Fmr1 knockout mice
(Fraser, CE thesis). These negative data indicate that global effects of FMRP in terms of
translational control at steady state is extremely subtle. Effects of FMRP may be local as
it is suggested by many studies that FMRP traffics mRNAs to synapses for local
translational regulation (Antar et al., 2004; Antar et al., 2005; De Diego Otero et al.,
2002; Muddashetty et al., 2007). Effects of FMRP may also be transient and activity
dependent (Hou et al., 2006; Todd et al., 2003). Therefore FMRP may spatially and
temporally fine-tune gene expression of its target mRNAs. Although globally we have
not been able to observe the changes of FMRP target metabolism, if we were able to
capture the right subcellular compartment at the right time, the effect of FMRP may not
be so subtle.
Last but not least, gene expression in eukaryotes undergoes many different control
steps regulated by various multi-protein complexes. In contrast to a simple linear
assembly line, a complex and extensive coupled network has evolved to coordinate the
activities of the different protein complexes (Maniatis and Reed, 2002). Studies of other
RBPs have shown that one RBP can have more than one role. The best understood
function of Hu is regulation of mRNA stability by binding to AU rich element in 3’UTR
of messages (Brennan et al., 2000; Deschenes-Furry et al., 2006; Keene, 1999). But other
functions have also been shown. When shuttling of HuD is blocked, neurite elongation is
severely impeded, suggesting that HuD plays an important role in trafficking and
localizing its transcripts, e.g. Tau mRNA is targeted to axons and GAP-43 to growth
cones (Deschenes-Furry et al., 2006). In our lab, Hu has also been shown to regulate
splicing of certain RNAs. Another example is Nova, a well characterized tissue specific
mammalian RNA-binding protein that regulates alternative splicing (Dredge and Darnell,
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2003; Ule et al., 2003; Ule et al., 2006). A genome wide screen has shown that 24% of
Nova-binding sites map to mature RNAs, most of them to the 3’UTR regions. Two thirds
of Nova proteins are present in the cytoplasm, indicating Nova may have functions in
cytoplasm, too. This may apply to FMRP as well. FMRP may be a multifunctional
protein contributing to different steps of gene expression.

Conclusion
In conclusion, we have combined mouse models and biochemical analysis to
demonstrate that RNA binding is a key function of FMRP. Particularly we have shown in
the mouse that loss of KH2 domain specific RNA binding is likely the primary cause for
polyribosome dissociation and thus loss of proper translational control, which in turn
contributes to the synaptic dysfunction underlying the cognitive and behavioral deficits
observed in the Fragile X Syndrome. Through RNA binding, FMRP regulates a defined
set of mRNA targets involved in cytoskeletal and synaptic functions to mediate normal
cognition. We propose FMRP may spatially and temporally fine-tune gene expression of
its mRNA targets, but in a precise, robust and instantaneous fashion.
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